<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="o">
		<monograph id="1" status="active" ha="yes">
			<mono_name> obinutuzumab</mono_name>
			<info>
				<pronunciation>(oh′bi-nue-tooz′ue-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x230">Gazyva</tradename>
				</tradenames>
				<class type="func"> Antineoplastic; biologic response modifier</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x29">
				<sec_title>Action:</sec_title>
				<para>A recombinant, human monoclonal antibody that binds to the gastric B-lymphocyte-associated antibody; action is indirect, possible through T-cell-mediated anti-tumor responses</para>
			</section>
			<section type="uses" id="sidelem4x34">
				<sec_title>Uses:</sec_title>
				<para>Chronic lymphocytic leukemia, previously untreated in combination</para>
			</section>
			<section type="contra" id="sidelem4x39">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x44">
					<section type="none" id="sidelem4x45">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, cardiac disease, children, human antichimeric antibody (HACA), human antimurine antibody (HAMA), infection, infusion-related reactions, neutropenia, pulmonary disease, thrombocytopenia, tumor lysis syndrome, vaccination</para>
						<para>
							<bbw>Hepatitis, progressive multifocal leukoencephalopathy</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x60">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x68">
					<label>•</label>
					<sec_title>Adult<route> IV cycle 1</route></sec_title>
					<para>
						<list id="lidelem4x68">
							<item>
								<label>•</label>
								<para> 100 mg over 4 hr (day 1); then 900 mg (50 mg/hr, increased by 50 mg/hr q30min, to max 400 mg/hr) (day 2); then 1000 mg (100 mg/hr, increased by 100 mg/hr q30min to max 400 mg/hr (day 8, day 115);  1000 mg (100 mg/hr increased by 100 mg/hr q30min to max 400 mg/hr (day 1 repeat q28days)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x75">
					<section type="none" id="sidelem4x76">
						<sec_title>Available forms:</sec_title>
						<para> Sol for inj 1000 mg/40 ml</para>
					</section>
					<section type="none" id="sidelem4x81">
						<sec_title>Administer:</sec_title>
						<para/>
						<section type="none" id="sidelem4x85">
							<sec_title>IV intermittent INFUSION route</sec_title>
							<para>
								<list id="lidelem4x90">
									<item>
										<label>•</label>
										<para>Due to the risk of hypotension, consider withholding antihypertensive medications for 12 hr before, during, and for the 1st hr after use until blood pressure is stable</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x95">
									<item>
										<label>•</label>
										<para>Single-use vials do not contain preservatives</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x100">
									<item>
										<label>•</label>
										<para>Do not mix with other products</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x105">
									<item>
										<label>•</label>
										<para>Give antimicrobial prophylaxis to neutropenic patients throughout treatment; consider antiviral and antifungal prophylaxis as needed</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x113">
								<label>•</label>
								<sec_title>Premedication for cycle 1, days 1 and 2</sec_title>
								<para>
									<list id="lidelem4x113">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Premedication for cycle 1, days 1 and 2:</emphasis> acetaminophen 650-1000 mg, and diphenhydrAMINE 50 mg at least 30 min before infusion, dexamethasone 20 mg IV or methylPREDNISolone 80 mg IV at least 1 hr before infusion</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x120">
								<label>•</label>
								<sec_title>Premedication for cycle 1, days 8 and 15 and cycles 2-6, day 1</sec_title>
								<para>
									<list id="lidelem4x120">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Premedication for cycle 1, days 8 and 15 and cycles 2-6, day 1:</emphasis> acetaminophen 650-1000 mg at least 30 min before infusion; those with any infusion-related reaction with the previous infusion should also receive diphenhydrAMINE 50 mg at least 30 min before the infusion; if the patient had a grade 3 infusion-related reaction with the previous dose or has a lymphocyte count &gt;25 × 10<emphasis style="sup">9</emphasis>/L, additionally administer dexamethasone 20 mg IV or methylPREDNISolone 80 mg IV at least 1 hr before infusion</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x127">
									<item>
										<label>•</label>
										<para>Use in a facility to adequately monitor and treat infusion reactions</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x132">
									<item>
										<label>•</label>
										<para>Visually inspect parenteral products for particulate matter and discoloration before use</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x137">
									<item>
										<label>•</label>
										<para>Prepare all doses in 0.9% NaCl; do not admix; use a final concentration of 0.4-4 mg/mL; give as an IV infusion only</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x142">
							<sec_title>Reconstitution: Cycle 1, days 1 and 2:</sec_title>
							<para>
								<list id="lidelem4x146">
									<item>
										<label>•</label>
										<para>Withdraw 4 mL (100 mg) from the vial and dilute into 100 mL 0.9% NaCL use on day 1; mix by gentle inversion; do not shake, use immediately</para>
									</item>
									<item>
										<label>•</label>
										<para>Withdraw the remaining 36 mL (900 mg) and dilute into 250 mL 0.9% NaCl for use on day 2, mix by gentle inversion; do not shake</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x157">
							<sec_title>Cycle 1, days 8 and 15; cycles 2-6:</sec_title>
							<para>
								<list id="lidelem4x162">
									<item>
										<label>•</label>
										<para>Withdraw 40 mL (1000 mg) from the vial and dilute into 250 mL 0.9% NaCl; mix by gentle inversion; do not shake</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x167">
									<item>
										<label>•</label>
										<para>Store following reconstitution: store at 2° C-8° C (36° F-46° F) for up to 24 hr; do not freeze; allow to come to room temperature before administration; use a dedicated line, protect from light</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x177">
								<label>•</label>
								<sec_title>Day 1 (100 mg dose)</sec_title>
								<para>
									<list id="lidelem4x177">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">
													<emphasis style="italic">Day 1 (100 mg dose):</emphasis>
												</emphasis> give at initial rate of 25 mg/hr over 4 hr; do not increase the infusion rate</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x185">
								<label>•</label>
								<sec_title>Day 2 (900 mg dose)</sec_title>
								<para>
									<list id="lidelem4x185">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">
													<emphasis style="italic">Day 2 (900 mg dose):</emphasis>
												</emphasis> give at 50 mg/hr ×30 min; if no hypersensitivity or infusion-related events occur, increase the rate by 50 mg/hr q30min to a max rate of 400 mg/hr; if a grade 1-2 infusion-related reaction occurs, temporarily interrupt or reduce rate; the infusion may be resumed at a reduced rate upon improvement; if the reaction does not recur, the rate may be increased for the current cycle and dose; if a grade 3 hypersensitivity or infusion-related event develops, the infusion should be temporarily interrupted; upon improvement, the infusion can be resumed at half the rate at the time that the reaction occurred; if the reaction does not recur, the rate may be increased; if a grade 4 hypersensitivity or infusion-related event develops, discontinue the infusion and do not resume</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x193">
								<label>•</label>
								<sec_title>Subsequent infusions (1000 mg dose)</sec_title>
								<para>
									<list id="lidelem4x193">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">
													<emphasis style="italic">Subsequent infusions (1000 mg dose):</emphasis>
												</emphasis> give at rate of 100 mg/hr for 30 min; if no hypersensitivity or infusion-related events occur, increase the infusion rate by 100 mg/hr q30min, max rate of 400 mg/hr; if a grade 1-2 infusion-related reaction occurs, the infusion should be temporarily interrupted or the rate reduced; the infusion may be resumed at a reduced rate upon improvement; if the reaction does not recur, the rate may be increased for the current cycle and dose; if a grade 3 hypersensitivity or infusion-related event develops, temporarily interrupt; upon improvement, resume at half the rate being used at the time that the reaction occurred; if the reaction does not recur, the rate may be increased for the current cycle and dose; if a grade 4 hypersensitivity or infusion-related event develops, discontinue the infusion and do not resume</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x199">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x202">
					<section type="none" id="sidelem4x203">
						<sec_title>CNS:</sec_title>
						<para> Headache, fever, chills, flushing</para>
					</section>
					<section type="none" id="sidelem4x208">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Cardiac arrest, MI, sinus tachycardia,</emphasis> hypertension</para>
					</section>
					<section type="none" id="sidelem4x216">
						<sec_title>GI:</sec_title>
						<para> Constipation, decreased appetite, diarrhea, <emphasis style="bold">hepatitis/hepatic failure,</emphasis> nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x224">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, thrombocytopenia, lymphopenia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x231">
						<sec_title>META:</sec_title>
						<para> Lower potassium/sodium/calcium, aluminum, higher potassium/uric acid</para>
					</section>
					<section type="none" id="sidelem4x236">
						<sec_title>RESP:</sec_title>
						<para> Wheezing, dyspnea</para>
					</section>
					<section type="none" id="sidelem4x241">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Tumor lysis syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x248">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Terminal half-life 28.4 days</para>
			</section>
			<section type="interactions" id="sidelem4x253">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions—abciximab, belimumab, clozapine, pimecrolimus, avoid concurrent use</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> infection—denosumab, natalizumab, live virus vaccines</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—antihypertensives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> thrombocytopenia—chlorambucil</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hematologic toxicity—leflunomide</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> immunosuppression—tofacitinib, avoid concurrent use</para>
				<section type="none" id="sidelem4x280">
					<section type="none" id="sidelem4x281">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> obinutuzumab—echinacea</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x288">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x291">
					<section type="none" id="sidelem4x292">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Hepatitis B: reactivation of HBV in those who are HBsAg positive, HBsAg negative, and core antibody anti-HBc positive; may result in fulminant hepatitis, hepatic failure, or death, screen high-risk patients before use, monitor carriers for active HBV infection during and for several months after therapy completion, discontinue treatment of any other antineoplastics if infection is reactivated</bbw>
						</para>
						<para>
							<bbw>Progressive multifocal leukoencephalopathy (PML): notify prescriber any new, worsening neurological signs/symptoms (ataxia, visual changes, confusion)</bbw>
						</para>
						<section type="none" id="sidelem4x319">
							<label>•</label>
							<sec_title>Tumor lysis syndrome<route> can occur within 24 hr of 1st infusion; those with high tumor burden or lymphocyte count &gt;25 × 109/L are at increased risk; monitor serum creatinine, potassium, calcium, uric acid, phosphate closely</route></sec_title>
						</section>
						<section type="none" id="sidelem4x328">
							<label>•</label>
							<sec_title>Severe/life-threatening infusion reactions<route> 2/3 have a reaction to 1st dose; consider withholding antihypertensives for 12 hr before, during, and after 1st hr of infusion</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x331">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x335">
								<item>
									<label>•</label>
									<para>Decreased disease progression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x341">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x349">
							<para>
								<list id="lidelem4x349">
									<item>
										<label>•</label>
										<para>About the reason for treatment and expected results
<bbw>
												<emphasis alert="lifethreat">Hepatitis B:</emphasis> to report yellow skin, eyes, fatigue, dark urine, that continuing follow-up will be needed</bbw>

<bbw>
												<emphasis alert="lifethreat">Progressive multifocal leukoencephalopathy (PML):</emphasis> to report confusion, visual changes, dizziness</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>octreotide (Rx)</mono_name>
			<info>
				<pronunciation>(ok-tree′oh-tide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x3781">SandoSTATIN</tradename>
					<tradename id="tnidelem4x3780">SandoSTATIN LAR Depot</tradename>
				</tradenames>
				<class type="func"> Growth hormone, antidiarrheal</class>
				<class type="chem"> Synthetic octapeptide</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x388">
				<sec_title>Action:</sec_title>
				<para>A potent growth hormone similar to somatostatin</para>
			</section>
			<section type="uses" id="sidelem4x393">
				<sec_title>Uses:</sec_title>
				<para>
					<emphasis style="bold">SandoSTATIN:</emphasis> acromegaly, improves symptoms of carcinoid tumors, vasoactive intestinal peptide tumors (VIPomas); <emphasis style="bold">LAR Depot:</emphasis> long-term maintenance of acromegaly, carcinoid tumors, VIPomas</para>
				<section type="none" id="sidelem4x403">
					<section type="none" id="sidelem4x404">
						<sec_title>Unlabeled uses:</sec_title>
						<para> GI fistula, variceal bleeding, diarrheal conditions, pancreatic fistula, irritable bowel syndrome, dumping syndrome, short bowel syndrome, insulinoma, hepatorenal syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x409">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x414">
					<section type="none" id="sidelem4x415">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, diabetes mellitus, hypothyroidism, renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x420">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x423">
					<section type="none" id="sidelem4x424">
						<sec_title>Acromegaly</sec_title>
						<section type="none" id="sidelem4x432">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x432">
									<item>
										<label>•</label>
										<para> (SandoSTATIN) 50-100 mcg bid-tid, adjust q2wk based on growth hormone levels or  (SandoSTATIN LAR) 20 mg q4wk × 3 mo, adjust based on growth hormone levels</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x439">
						<sec_title>VIPomas</sec_title>
						<section type="none" id="sidelem4x447">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x447">
									<item>
										<label>•</label>
										<para> (SandoSTATIN) 200-300 mcg/day in 2-4 doses for 2 wk, or  (SandoSTATIN LAR) 20 mg q4wk × 2 mo, adjust dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x454">
						<sec_title>Flushing/diarrhea in carcinoid tumors</sec_title>
						<section type="none" id="sidelem4x462">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x462">
									<item>
										<label>•</label>
										<para> (SandoSTATIN) 100-600 mcg/day in 2-4 doses for 2 wk, titrated to patient response or  (SandoSTATIN LAR) 20 mg q4wk × 2 mo, adjust dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x469">
						<sec_title>GI fistula</sec_title>
						<section type="none" id="sidelem4x477">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x477">
									<item>
										<label>•</label>
										<para> (SandoSTATIN) 50-200 mcg q8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x481">
						<sec_title>Antidiarrheal in AIDS patients (unlabeled)</sec_title>
						<section type="none" id="sidelem4x489">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x489">
									<item>
										<label>•</label>
										<para> (SandoSTATIN) 50 mcg q8hr prn, increase to 500 mcg q8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x493">
						<sec_title>Irritable bowel syndrome (unlabeled)</sec_title>
						<section type="none" id="sidelem4x501">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x501">
									<item>
										<label>•</label>
										<para> (SandoSTATIN) 100 mcg in single dose, up to 125 mcg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x505">
						<sec_title>Dumping syndrome (unlabeled)</sec_title>
						<section type="none" id="sidelem4x513">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x513">
									<item>
										<label>•</label>
										<para> (SandoSTATIN) 50-150 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x518">
						<sec_title>Chemotherapy-induced diarrhea (unlabeled)</sec_title>
						<section type="none" id="sidelem4x526">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x526">
									<item>
										<label>•</label>
										<para> 0.1-0.5 mg or IV 0.15-2.4 mg/24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x530">
						<sec_title>Variceal bleeding (unlabeled)</sec_title>
						<section type="none" id="sidelem4x538">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x538">
									<item>
										<label>•</label>
										<para> (SandoSTATIN) 25-50 mcg/hr  for 18 hr-5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x545">
						<sec_title>Available forms:</sec_title>
						<para> Inj (SandoSTATIN) 0.05, 0.1, 0.2, 0.5, 1 mg/ml; inj powder for susp (LAR depot) 10, 20, 30 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x550">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x554">
								<item>
									<label>•</label>
									<para>Store in refrigerator for unopened amps, vials or at room temperature for 2 wk; protect from light; do not use discolored or cloudy sol</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not use if discolored or particulates are present</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x565">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x569">
									<item>
										<label>•</label>
										<para>Reconstitute with diluent provided; give in gluteal region, rotate injection sites</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x575">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x579">
									<item>
										<label>•</label>
										<para>Rotate inj site; use hip, thigh, abdomen</para>
									</item>
									<item>
										<label>•</label>
										<para>Avoid using medication that is cold; allow to reach room temperature; do not use LAR depot, do not use if discolored or if particulates are present</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x590">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x598">
								<label>•</label>
								<sec_title>IV direct</sec_title>
								<para>
									<list id="lidelem4x598">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">IV direct:</emphasis> give over 3 min; during an emergency carcinoid crisis, give rapid bolus</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x605">
								<label>•</label>
								<sec_title>Intermittent IV infusion</sec_title>
								<para>
									<list id="lidelem4x605">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Intermittent IV infusion:</emphasis> dilute in 50-200 ml D<emphasis style="inf">5</emphasis>W, 0.9% NaCl; give over 15-30 min</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x612">
									<item>
										<label>•</label>
										<para>Solution is stable for 24 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B colloidal, amphotericin B lipid complex, amphotericin B liposome, ampicillin, ampicillin-sulbactam, anidulafungin, argatroban, arsenic trioxide, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, busulfan, butorphanol, calcium chloride/gluconate, capreomycin, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DACTINomycin, DAPTOmycin, DAUNOrubicin, DAUNOrubicin liposome, dexamethasone, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, gallium nitrate, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, lansoprazole, leucovorin, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, mesna, methohexital, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoMYcin, mitoXANtrone, mivacurium, morphine, moxifloxacin, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, oxaliplatin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin-tazobactam, polymyxin B, potassium acetate/chloride/phosphates, procainamide, prochlorperazine, promethazine, propranolol, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, rocuronium, sodium acetate/bicarbonate/phosphates, streptozocin, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, topotecan, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x623">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x626">
					<section type="none" id="sidelem4x627">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness, fatigue, weakness,</emphasis> depression, anxiety, tremors, <emphasis style="bold">seizure,</emphasis> paranoia</para>
					</section>
					<section type="none" id="sidelem4x638">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Sinus bradycardia, conduction abnormalities,</emphasis><emphasis style="bold">dysrhythmias,</emphasis> chest pain, SOB, thrombophlebitis, ischemia, <emphasis style="bold">CHF,</emphasis> hypertension, palpitations, <emphasis style="bold">QT prolongation, ST- or T-wave changes</emphasis></para>
					</section>
					<section type="none" id="sidelem4x653">
						<sec_title>ENDO:</sec_title>
						<para> <emphasis style="italic">Hypo/hyperglycemia, ketosis, hypothyroidism,</emphasis> galactorrhea, diabetes insipidus</para>
					</section>
					<section type="none" id="sidelem4x661">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, nausea, abdominal pain, vomiting, flatulence, distention, constipation,</emphasis><emphasis style="bold">hepatitis,</emphasis> increased LFTs, <emphasis style="bold">GI bleeding, pancreatitis,</emphasis> cholelithiasis, ileus</para>
					</section>
					<section type="none" id="sidelem4x674">
						<sec_title>GU:</sec_title>
						<para> UTI</para>
					</section>
					<section type="none" id="sidelem4x679">
						<sec_title>HEMA:</sec_title>
						<para> Hematoma of inj site, bruise</para>
					</section>
					<section type="none" id="sidelem4x684">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, pain; inflammation at inj site</para>
					</section>
					<section type="none" id="sidelem4x689">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Joint and muscle pain</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x696">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorbed rapidly, completely; peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr (subcut/IV), 2-3 wk (IM); half-life 1.7 hr, duration 12 hr, excreted unchanged in urine</para>
			</section>
			<section type="interactions" id="sidelem4x707">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol, pentamidine; CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin), arsenic trioxide, levomethadyl; CYP3A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperiDONE, ziprasidone)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of β-blockers, reduction of dose may be required</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of insulin, oral antidiabetics, monitor blood glucose</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> excretion of CYP3A4 metabolized products, reduction of dose may be required</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of bromocriptine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—cycloSPORINE</para>
				<section type="none" id="sidelem4x735">
					<section type="none" id="sidelem4x736">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption of dietary fat, vit B<emphasis style="inf">12</emphasis> levels</para>
					</section>
					<section type="none" id="sidelem4x746">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> T<emphasis style="inf">4</emphasis>, thyroid function tests, vit B<emphasis style="inf">12</emphasis>, glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x763">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x766">
					<section type="none" id="sidelem4x767">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x775">
							<label>•</label>
							<sec_title>
								<route>(acromegaly)</route>
							</sec_title>
							<para>
								<list id="lidelem4x775">
									<item>
										<label>•</label>
										<para>Growth hormone antibodies, IGF-1 at 1- to 4-hr intervals for 8-12 hr after dose ; 5-HIAA, plasma serotonin; blood glucose, serotonin levels , plasma substance P, plasma vasoactive intestinal peptide </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x785">
								<item>
									<label>•</label>
									<para>Thyroid function tests: T<emphasis style="inf">3</emphasis>, T<emphasis style="inf">4</emphasis>, T<emphasis style="inf">7</emphasis>, TSH to identify hypothyroidism</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x799">
								<item>
									<label>•</label>
									<para>Fecal fat, serum carotene, somatomedin-C q14days, glucose; plasma serotonin levels (carcinoid tumors); plasma vasoactive intestinal peptide levels (VIPoma); serum growth hormone, serum IGF-1 baseline and periodically, diabetes to monitor blood glucose</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x807">
							<label>•</label>
							<sec_title>Allergic reaction</sec_title>
							<para>
								<list id="lidelem4x807">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reaction:</emphasis> rash, itching, fever, nausea, wheezing</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x812">
								<item>
									<para>
										<emphasis alert="nurse">Cardiac status: bradycardia, conduction abnormalities, dysrhythmias; monitor ECG for QT prolongation, low voltage, axis shifts, early repolarization, R/S transition, early wave progression</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x817">
								<item>
									<label>•</label>
									<para>Gall bladder disease, pancreatitis: monitor closely</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x822">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x826">
								<item>
									<label>•</label>
									<para>Therapeutic response: relief of diarrhea in patients with AIDS; improved symptoms of carcinoid or VIP tumors; decreasing symptoms of acromegaly</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x832">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x837">
								<item>
									<label>•</label>
									<para>That regular assessments are required; diabetics to monitor blood glucose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x843">
								<item>
									<label>•</label>
									<para>About SUBCUT inj if patient or other persons will be giving inj</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x849">
								<item>
									<para>
										<emphasis alert="nurse">That product may cause dizziness, drowsiness, weakness; to avoid hazardous activities if these occur; to report abdominal pain immediately</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x857">
							<label>•</label>
							<sec_title>
								<route>That pregnancy may occur in acromegaly because fertility may be restored</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x860">
								<item>
									<label>•</label>
									<para>That in diabetes, to monitor glucose regularly</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>ofloxacin (Rx)</mono_name>
			<info>
				<pronunciation>(o-flox′a-sin)</pronunciation>
				<class type="func"> Antiinfective</class>
				<class type="chem"> Fluoroquinolone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x878">
				<sec_title>Action:</sec_title>
				<para>Interferes with conversion of intermediate DNA fragments into high-molecular-weight DNA in bacteria; inhibits DNA gyrase</para>
			</section>
			<section type="uses" id="sidelem4x883">
				<sec_title>Uses:</sec_title>
				<para>Treatment of lower respiratory tract infections (pneumonia, bronchitis), genitourinary infections (prostatitis, UTIs) caused by <emphasis style="italic">Escherichia coli, Klebsiella pneumoniae, Chlamydia trachomatis,</emphasis> skin and skin-structure infections; otitis media, PID</para>
				<section type="none" id="sidelem4x891">
					<section type="none" id="sidelem4x892">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Leprosy, anthrax, epididymitis, meningococcal infection, prophylaxis, mycobacterium avium complex (MAC), plague, proctitis, traveler’s diarrhea, typhoid fever, TB</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x897">
				<sec_title>Contraindications:</sec_title>
				<para>QT prolongation, hypersensitivity to quinolones</para>
				<section type="none" id="sidelem4x902">
					<section type="none" id="sidelem4x903">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, renal disease, seizure disorders, excessive sunlight, hypokalemia, colitis</para>
						<para>
							<bbw>Tendon pain/rupture, tendinitis, myasthenia gravis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x918">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x921">
					<section type="none" id="sidelem4x922">
						<sec_title>Lower respiratory tract infections/skin and skin-structure infections</sec_title>
						<section type="none" id="sidelem4x930">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x930">
									<item>
										<label>•</label>
										<para> 400 mg q12hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x934">
						<sec_title>Prostatitis from <emphasis style="bold">
								<emphasis style="italic">E. coli</emphasis>
							</emphasis></sec_title>
						<section type="none" id="sidelem4x945">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x945">
									<item>
										<label>•</label>
										<para> 300 mg q12hr × 6 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x949">
						<sec_title>Urinary tract infection</sec_title>
						<section type="none" id="sidelem4x957">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x957">
									<item>
										<label>•</label>
										<para> 200 mg q12hr × 3-7 days depending on organism 10 days (complicated)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x961">
						<sec_title>Pelvic inflammatory disease</sec_title>
						<section type="none" id="sidelem4x969">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x969">
									<item>
										<label>•</label>
										<para> 400 mg q12hr with metronidazole × 10-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x973">
						<sec_title>Traveler’s diarrhea (unlabeled)</sec_title>
						<section type="none" id="sidelem4x981">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x981">
									<item>
										<label>•</label>
										<para> 200 mg bid × 3 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x985">
						<sec_title>Epididymitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x993">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x993">
									<item>
										<label>•</label>
										<para> 300 mg bid × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x997">
						<sec_title>Spontaneous bacterial peritonitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1005">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1005">
									<item>
										<label>•</label>
										<para> 400 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1009">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x1017">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 20-50 ml/min, give q24hr; CCr &lt;20 ml/min, give 50% of dose q24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1020">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x1028">
							<label>•</label>
							<sec_title>Adult (Child-Pugh class C)<route> PO max 400 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1031">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 200, 300, 400 mg</para>
					</section>
					<section type="none" id="sidelem4x1036">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1039">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1043">
									<item>
										<label>•</label>
										<para>2 hr before or 2 hr after antacids, calcium, iron, zinc products, without regard to food, maintain hydration</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature, protect from light</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1054">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1057">
					<section type="none" id="sidelem4x1058">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache, fatigue, somnolence,</emphasis> depression, insomnia, lethargy, malaise, <emphasis style="bold">seizures,</emphasis> vertigo</para>
					</section>
					<section type="none" id="sidelem4x1069">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">QT prolongation, dysrhythmias,</emphasis> chest pain</para>
					</section>
					<section type="none" id="sidelem4x1077">
						<sec_title>EENT:</sec_title>
						<para> Visual disturbances, pharyngitis</para>
					</section>
					<section type="none" id="sidelem4x1082">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, nausea, vomiting,</emphasis> anorexia, flatulence, heartburn, dry mouth, increased AST, ALT, abdominal pain, constipation, <emphasis style="bold">pseudomembranous colitis,</emphasis> abnormal taste, xerostomia</para>
					</section>
					<section type="none" id="sidelem4x1093">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Blood dyscrasias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1100">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x1105">
						<sec_title>MS:</sec_title>
						<para> Tendinitis, <emphasis style="bold">tendon rupture, rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1113">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1120">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x1123">
					<section type="none" id="sidelem4x1124">
						<sec_title>PO:</sec_title>
						<para> Peak 1-2 hr; half-life 4-8 hr; steady-state 2 days; excreted in urine as active product, metabolites; 90%-95% bioavailability</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1129">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> tendon rupture/tendinitis—corticosteroids</bbw>
				</para>
				<para>
					<list id="lidelem4x1145">
						<item>
							<label>•</label>
							<para>May alter blood glucose levels: antidiabetics</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x1153">
					<label>•</label>
					<sec_title>Possible theophylline toxicity<route> theophylline</route></sec_title>
				</section>
				<para>
					<list id="lidelem4x1157">
						<item>
							<para>
								<emphasis alert="nurse">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β-agonists, local anesthetics, tricyclics, haloperidol, methadone, chloroquine, clarithromycin, droperidol, erythromycin, pentamidine</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS stimulation, seizures—NSAIDs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticoagulation—warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> ofloxacin—sevelamer</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—antacids with aluminum, magnesium, iron products, sucralfate, zinc products; separate by 2 hr</para>
				<section type="none" id="sidelem4x1178">
					<section type="none" id="sidelem4x1179">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> INR</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1186">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1189">
					<section type="none" id="sidelem4x1190">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Tendon rupture/tendinitis:</emphasis> more common in lung, heart, kidney transplants or geriatric patients; assess for pain or inflammation</bbw>
						</para>
						<para>
							<list id="lidelem4x1206">
								<item>
									<label>•</label>
									<para>Blood studies: BUN, creatinine, AST, ALT, CBC, blood glucose, INR (warfarin use)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1214">
							<label>•</label>
							<sec_title>CNS symptoms</sec_title>
							<para>
								<list id="lidelem4x1214">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CNS symptoms:</emphasis> insomnia, vertigo, headache, agitation, confusion</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<bbw>Myasthenia gravis: product may increase weakness, avoid use</bbw>
						</para>
						<para>
							<list id="lidelem4x1229">
								<item>
									<label>•</label>
									<para>For overgrowth of infection in long-term treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1237">
							<label>•</label>
							<sec_title>Allergic reactions</sec_title>
							<para>
								<list id="lidelem4x1237">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reactions:</emphasis> rash, flushing, urticaria, pruritus, stop product if these occur</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1241">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1245">
								<item>
									<label>•</label>
									<para>Therapeutic response: urine culture, absence of symptoms of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1251">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1256">
								<item>
									<label>•</label>
									<para>That if dizziness or light-headedness occur, to ambulate, perform activities with assistance</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1261">
								<item>
									<label>•</label>
									<para>To complete full course of therapy; take with plenty of fluids</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1266">
								<item>
									<label>•</label>
									<para>To avoid iron- or mineral-containing supplements within 2 hr before or after dose; take without regard to meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1271">
								<item>
									<label>•</label>
									<para>That allergic reactions usually occur after first dose but may occur later; stop product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1276">
								<item>
									<label>•</label>
									<para>To avoid sun exposure; photosensitivity can occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1281">
								<item>
									<label>•</label>
									<para>To avoid use with other products unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1289">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber immediately if tingling, pain in extremities occur</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active">
			<mono_name>ofloxacin ophthalmic</mono_name>
			<section type="none" id="sidelem4x1295">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="5" status="active">
			<mono_name>OLANZapine (Rx)</mono_name>
			<info>
				<pronunciation>(oh-lanz′a-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x13042">Zyprexa</tradename>
					<tradename id="tnidelem4x13041">Zyprexa Relprevv</tradename>
					<tradename id="tnidelem4x13040">Zyprexa Zydis</tradename>
				</tradenames>
				<class type="func"> Antipsychotic, neuroleptic</class>
				<class type="chem"> Thienobenzodiazepine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1314">
				<para>
					<confusion>
						<tradename id="tnidelem4x13140">OLANZapine</tradename>
						<drug type="generic" refid="idelem4x13140">osalazine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1321">
				<sec_title>Action:</sec_title>
				<para>May mediate antipsychotic activity by both DOPamine and serotonin type 2 (5-HT2) antagonists; may antagonize muscarinic receptors, histaminic (H<emphasis style="inf">1</emphasis>)- and α-adrenergic receptors</para>
			</section>
			<section type="uses" id="sidelem4x1330">
				<sec_title>Uses:</sec_title>
				<para>Schizophrenia, acute manic episodes with bipolar disorder, acute agitation</para>
				<section type="none" id="sidelem4x1335">
					<section type="none" id="sidelem4x1336">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Acute psychosis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1341">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x1346">
					<section type="none" id="sidelem4x1347">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, hypertension, cardiac/renal/hepatic disease, diabetes, agranulocytosis, abrupt discontinuation, Asian patients, closed-angle glaucoma, coma, leukopenia, QT prolongation, tardive dyskinesia, torsades de pointes, suicidal ideation, stroke history, TIA</para>
						<para>
							<bbw>Increased mortality in elderly patients with dementia-related psychosis, postinjection delirium/sedation syndrome</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1362">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1365">
					<section type="none" id="sidelem4x1366">
						<sec_title>Schizophrenia</sec_title>
						<section type="none" id="sidelem4x1374">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1374">
									<item>
										<label>•</label>
										<para> 5-10 mg/day initially, may increase dosage by 5 mg at ≥1 wk intervals, max 20 mg/day;  tabs: open blister pack, place tab on tongue, let disintegrate, swallow;  (Zyprexa Relprevv)  150-300 mg q2wk or 405 mg q4wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1390">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1390">
									<item>
										<label>•</label>
										<para> 5 mg, may increase cautiously at 1-wk intervals, max 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1397">
							<label>•</label>
							<sec_title>Adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1397">
									<item>
										<label>•</label>
										<para> 2.5 or 5 mg/day, target 10 mg/day, max 20 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1404">
							<label>•</label>
							<sec_title>Child 6-12 yr (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1404">
									<item>
										<label>•</label>
										<para> 2.5 mg daily, may increase to 5 mg/day after 4-7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1408">
						<sec_title>Bipolar mania</sec_title>
						<section type="none" id="sidelem4x1416">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1416">
									<item>
										<label>•</label>
										<para> 10-15 mg/day, may increase dose after &gt;24 hr by 5 mg, max 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1423">
							<label>•</label>
							<sec_title>Adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1423">
									<item>
										<label>•</label>
										<para> 2.5 or 5 mg/day, target 10 mg/day, max 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1427">
						<sec_title>Agitation associated with schizophrenia, bipolar I mania</sec_title>
						<section type="none" id="sidelem4x1435">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x1435">
									<item>
										<label>•</label>
										<para> (reg rel) 10 mg once</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1442">
							<label>•</label>
							<sec_title>Geriatric<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x1442">
									<item>
										<label>•</label>
										<para> (reg rel) 2.5-5 mg once</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1446">
						<sec_title>Severe behavioral disturbances in geriatric patients (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1454">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1454">
									<item>
										<label>•</label>
										<para> 2.5-5 mg/day;  5-10 mg every night</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1461">
						<sec_title>Obsessive compulsive disorder (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1469">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1469">
									<item>
										<label>•</label>
										<para> 5 mg daily, may increase as needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1473">
						<sec_title>Tourette syndrome (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1481">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1481">
									<item>
										<label>•</label>
										<para> 5 mg daily titrate to 20 mg daily × 6-8 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1485">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">Tab</emphasis> 2.5, 5, 7.5, 10, 15, 20 mg; <emphasis style="bold">orally disintegrating tabs</emphasis> 5, 10, 15, 20 mg (Zyprexia Zydis); <emphasis style="bold">powder for inj</emphasis> 10 mg; <emphasis style="bold">ext rel powder for susp for inj</emphasis> 210, 300, 405 mg (Zyprexa Relprevv)</para>
					</section>
					<section type="none" id="sidelem4x1502">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1506">
								<item>
									<label>•</label>
									<para>Decreased dose in geriatric patients</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1512">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1517">
									<item>
										<label>•</label>
										<para>With full glass of water, milk, food to decrease GI upset</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1522">
									<item>
										<label>•</label>
										<para>Store in tight, light-resistant container</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x1530">
								<label>•</label>
								<sec_title>Orally disintegrating tabs</sec_title>
								<para>
									<list id="lidelem4x1530">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Orally disintegrating tabs:</emphasis> open blister pack; place tab on tongue until dissolved; swallow; no water needed; do not break, crush, chew</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x1534">
							<sec_title>IM route (Zyprexa Intramuscular)</sec_title>
							<para>
								<list id="lidelem4x1538">
									<item>
										<label>•</label>
										<para>Dissolve contents of vials with 2.1 ml sterile water for inj (5 mg/ml); use immediately</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use IV or SUBCUT</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject slowly, deep into muscle mass</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1554">
							<sec_title>IM route (Zyprexa Relprevv)</sec_title>
							<para>
								<bbw>Available only through restricted distribution program due to postinjection delirium/sedation syndrome; given at a facility with emergency services; continuous observation</bbw>
							</para>
							<para>
								<list id="lidelem4x1567">
									<item>
										<label>•</label>
										<para>Use deep IM gluteal inj only</para>
									</item>
									<item>
										<label>•</label>
										<para>Use only diluent provided in kit; give q2-4wk using 19-G, 1.5-inch needle in kit; for obese patients, use 19-G, 2-inch or larger needle</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1578">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1581">
					<section type="none" id="sidelem4x1582">
						<sec_title>CNS:</sec_title>
						<para> EPS: (pseudoparkinsonism, akathisia, dystonia, tardive dyskinesia), <emphasis style="bold">seizures,</emphasis> headache, <emphasis style="bold">neuroleptic malignant syndrome (rare),</emphasis> agitation, nervousness, hostility, <emphasis style="italic">dizziness,</emphasis> hypertonia, <emphasis style="italic">tremor,</emphasis> euphoria, confusion, <emphasis style="italic">drowsiness,</emphasis> fatigue, <emphasis style="italic">abnormal gait, insomnia, fever</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1605">
						<sec_title>CV:</sec_title>
						<para> Hypotension, tachycardia, chest pain, <emphasis style="bold">heart failure, sudden death (geriatric patients, IM),</emphasis> orthostatic hypotension, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x1613">
						<sec_title>ENDO:</sec_title>
						<para> Increased prolactin levels, hypo/hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x1618">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Dry mouth, nausea, vomiting, appetite, dyspepsia,</emphasis> anorexia, <emphasis style="italic">constipation,</emphasis> abdominal pain, <emphasis style="italic">weight gain,</emphasis> jaundice, <emphasis style="bold">hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1634">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, urinary frequency, enuresis, impotence, amenorrhea, gynecomastia, breast engorgement, premenstrual syndrome</para>
					</section>
					<section type="none" id="sidelem4x1639">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1646">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x1651">
						<sec_title>MISC:</sec_title>
						<para> Peripheral edema, accidental injury, hypertonia, hyperlipidemia</para>
					</section>
					<section type="none" id="sidelem4x1656">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Joint pain,</emphasis> twitching</para>
					</section>
					<section type="none" id="sidelem4x1664">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough, pharyngitis;</emphasis><emphasis style="bold">fatal pneumonia (geriatric patients, IM)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1673">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed (60%), metabolized by liver, glucuronidation/oxidation by CYP1A2 and CYP2D6; excreted in urine (57%), feces (30%); 93% bound to plasma proteins; half-life 21-54 hr, extended in geriatric patients; clearance decreased in women, increased in smokers, peak PO 6 hr, IM 15-45 min</para>
			</section>
			<section type="interactions" id="sidelem4x1678">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: serotonin syndrome, neuroleptic malignant syndrome—SSRIs, SNRIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> sedation—other CNS depressants, alcohol, barbiturate anesthetics, antihistamines, sedatives/hypnotics, antidepressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> OLANZapine levels—CYP1A2 inhibitors (fluvoxaMINE)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—antihypertensives, alcohol, diazepam</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic effects—anticholinergics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> OLANZapine levels—CYP1A2 inducers: carBAMazepine, omeprazole, rifampin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antiparkinson activity—levodopa, bromocriptine, other DOPamine agonists</para>
				<section type="none" id="sidelem4x1710">
					<section type="none" id="sidelem4x1711">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, prolactin, CPK</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1718">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1721">
					<section type="none" id="sidelem4x1722">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Postinjection delirium/sedation syndrome (Zyprexa Relprevv); monitor continuously for ≥3 hr after injection; patient must be accompanied when leaving: sedation, coma, delirium, EPS, slurred speech, altered gait, aggression, dizziness, weakness, hypertension, seizures; before leaving, confirm that patient is alert, oriented, and free of any other symptoms</bbw>
						</para>
						<para>
							<list id="lidelem4x1736">
								<item>
									<label>•</label>
									<para>Mental status: orientation, mood, behavior, presence of hallucinations and type before initial administration, monthly; EPS, including akathisia (inability to sit still, no pattern to movements), tardive dyskinesia (bizarre movements of jaw, mouth, tongue, extremities), pseudoparkinsonism (rigidity, tremors, pill rolling, shuffling gait)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1741">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; palpate bladder if low urinary output occurs, urinary retention may be cause, especially in geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1746">
								<item>
									<label>•</label>
									<para>Bilirubin, CBC, LFTs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1751">
								<item>
									<label>•</label>
									<para>Urinalysis recommended before, during prolonged therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1756">
								<item>
									<label>•</label>
									<para>Affect, orientation, LOC, reflexes, gait, coordination, sleep pattern disturbances</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1761">
								<item>
									<label>•</label>
									<para>B/P sitting, standing, lying: take pulse, respirations q4hr during initial treatment; establish baseline before starting treatment; report drops of 30 mm Hg; obtain baseline ECG</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1766">
								<item>
									<label>•</label>
									<para>Dizziness, faintness, palpitations, tachycardia on rising</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1772">
								<item>
									<para>
										<emphasis alert="nurse">Geriatric patients for serious reactions: fatal pneumonia, heart failure, stroke leading to death (IM)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1778">
								<item>
									<para>
										<emphasis alert="nurse">Neuroleptic malignant syndrome: hyperpyrexia, muscle rigidity, increased CPK, altered mental status, for acute dystonia (check chewing, swallowing, eyes, pill rolling)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1783">
								<item>
									<label>•</label>
									<para>Constipation, urinary retention daily; increase bulk, water in diet</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1789">
								<item>
									<label>•</label>
									<para>Weight gain, hyperglycemia, metabolic changes in diabetic patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1794">
								<item>
									<label>•</label>
									<para>Supervised ambulation until patient stabilized on medication; do not involve patient in strenuous exercise program because fainting is possible; patient should not stand still for long periods</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1799">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1803">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in emotional excitement, hallucinations, delusion, paranoia, reorganization of patterns of thought, speech</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1809">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>About postinjection delirium/sedation syndrome: teach about all symptoms</bbw>
						</para>
						<para>
							<list id="lidelem4x1823">
								<item>
									<label>•</label>
									<para>To use good oral hygiene; frequent rinsing of mouth; sugarless gum, candy, ice chips for dry mouth</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1828">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until product response is determined</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1833">
								<item>
									<label>•</label>
									<para>That orthostatic hypotension occurs often; to rise from sitting or lying position gradually</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1838">
								<item>
									<label>•</label>
									<para>To avoid hot tubs, hot showers, tub baths because hypotension may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1843">
								<item>
									<label>•</label>
									<para>To avoid abrupt withdrawal of this product because EPS may result; product should be withdrawn slowly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1848">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations (cough, hay fever, cold) unless approved by prescriber because serious product interactions may occur; to avoid use with alcohol, CNS depressants because increased drowsiness may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1856">
							<label>•</label>
							<sec_title>
								<route>That in hot weather, heat stroke may occur; to take extra precautions to stay cool</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x1859">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage if orally ingested; provide airway; do not induce vomiting or use EPINEPHrine</para>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>olaparib</mono_name>
			<info>
				<pronunciation>(oh-lap′a-rib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x18690">Lynparza</tradename>
				</tradenames>
				<class type="func"> Antineoplastic-PARP</class>
			</info>
			<section type="uses" id="sidelem4x1875">
				<sec_title>Uses:</sec_title>
				<para> Treatment of deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer in patients who have not responded successfully to ≥3 prior courses of chemotherapy, as monotherapy</para>
			</section>
			<section type="contra" id="sidelem4x1880">
				<sec_title>Contraindications:</sec_title>
				<para> Hypersensitivity</para>
			</section>
			<section type="doses" id="sidelem4x1885">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1893">
					<label>•</label>
					<sec_title>Adult females<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1893">
							<item>
								<label>•</label>
								<para> 400 mg bid, until disease progression or unacceptable toxicity. Avoid use of concomitant strong and moderate CYP3A4 inhibitors if possible</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>olmesartan (Rx)</mono_name>
			<info>
				<pronunciation>(ol-meh-sar′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x19020">Benicar</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin II receptor (type AT) antagonist</class>
			</info>
			<section type="confusion" id="sidelem4x1915">
				<para>
					<confusion>
						<tradename id="tnidelem4x19150">Benicar</tradename>
						<drug type="generic" refid="idelem4x19150">Mevacor</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1919">
				<sec_title>Action:</sec_title>
				<para>Blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II; selectively blocks the binding of angiotensin II to the AT<emphasis style="inf">1</emphasis> receptor found in tissues</para>
			</section>
			<section type="uses" id="sidelem4x1927">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or in combination with other antihypertensives</para>
			</section>
			<section type="contra" id="sidelem4x1932">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, pregnancy (D)</para>
				<section type="none" id="sidelem4x1937">
					<section type="none" id="sidelem4x1938">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, hepatic disease, CHF, renal artery stenosis, African descent, hyperkalemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1945">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1953">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1953">
							<item>
								<label>•</label>
								<para> single agent 20 mg/day initially in patients who are not volume depleted; may be increased to 40 mg/day if needed after 2 wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1960">
					<label>•</label>
					<sec_title>Child ≥6 yr/adolescents ≤16 yr weighing ≥35 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1960">
							<item>
								<label>•</label>
								<para> 20 mg/day; may increase to max 40 mg/day after 2 wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1967">
					<label>•</label>
					<sec_title>Child ≥6 yr/adolescents ≤16 yr weighing 20-&lt;35 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1967">
							<item>
								<label>•</label>
								<para> 10 mg daily; may increase to max 20 mg/day after 2 wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1971">
					<section type="none" id="sidelem4x1972">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 20, 40 mg</para>
					</section>
					<section type="none" id="sidelem4x1977">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1981">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Compounded suspension may be made in the pharmacy, refrigerate, shake well before use</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1992">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1995">
					<section type="none" id="sidelem4x1996">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness,</emphasis> fatigue, <emphasis style="italic">headache,</emphasis> insomnia, syncope</para>
					</section>
					<section type="none" id="sidelem4x2007">
						<sec_title>CV:</sec_title>
						<para> Chest pain, peripheral edema, tachycardia, <emphasis style="italic">hypotension</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2014">
						<sec_title>EENT:</sec_title>
						<para> Sinusitis, rhinitis, pharyngitis</para>
					</section>
					<section type="none" id="sidelem4x2019">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea,</emphasis> abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x2027">
						<sec_title>META:</sec_title>
						<para> <emphasis style="bold">Hyperkalemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2034">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, pain, rhabdomyolysis</para>
					</section>
					<section type="none" id="sidelem4x2039">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Upper respiratory infection,</emphasis> bronchitis</para>
					</section>
					<section type="none" id="sidelem4x2047">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2054">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-2 hr; excreted in urine, feces; half-life 13 hr; protein binding 99%</para>
			</section>
			<section type="interactions" id="sidelem4x2059">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> antihypertensive effects—other antihypertensives, diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—potassium supplements, potassium-sparing diuretics, ACE inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of lithium, antioxidants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs, colesevelan</para>
				<section type="none" id="sidelem4x2078">
					<section type="none" id="sidelem4x2079">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2090">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2093">
					<section type="none" id="sidelem4x2094">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Pregnancy;</emphasis> product can cause fetal death when given during pregnancy (D) 2nd/3rd trimesters</bbw>
						</para>
						<para>
							<list id="lidelem4x2110">
								<item>
									<label>•</label>
									<para>Response, adverse reactions, especially in renal disease; monitor renal function</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2118">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x2118">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P, pulse q4hr; note rate, rhythm, quality; electrolytes: sodium, potassium, chloride; baselines for renal, hepatic studies before therapy begins</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2125">
							<label>•</label>
							<sec_title>Hypotension</sec_title>
							<para>
								<list id="lidelem4x2125">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypotension:</emphasis> place supine; may occur with hyponatremia or those with volume depletion; more common in those taking a diuretic also</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2129">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2133">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2139">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2143">
								<item>
									<label>•</label>
									<para>To comply with dosage schedule, even if feeling better</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of mouth sores, fever, swelling of hands or feet, irregular heartbeat, chest pain</para>
								</item>
								<item>
									<label>•</label>
									<para>That excessive perspiration, dehydration, vomiting, diarrhea may lead to fall in B/P; to consult prescriber if these occur; to maintain adequate hydration</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may cause dizziness, fainting, lightheadedness; to avoid hazardous activities</para>
								</item>
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension
<bbw>To notify prescriber immediately if pregnant; not to use during breastfeeding</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid all OTC medications unless approved by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>That blood glucose may increase and antidiabetic product may need dosage change</para>
								</item>
								<item>
									<label>•</label>
									<para>To inform all health care providers of medication use</para>
								</item>
								<item>
									<label>•</label>
									<para>To use proper technique for obtaining B/P, acceptable parameters</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>olopatadine nasal agent</mono_name>
			<section type="none" id="sidelem4x2202">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="9" status="active">
			<mono_name>olopatadine ophthalmic</mono_name>
			<section type="none" id="sidelem4x2209">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>olsalazine (Rx)</mono_name>
			<info>
				<pronunciation>(ohl-sal′ah-zeen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x22180">Dipentum</tradename>
				</tradenames>
				<class type="func"> Antiinflammatory</class>
				<class type="chem"> Salicylate derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2228">
				<para>
					<confusion>
						<tradename id="tnidelem4x22280">olsalazine</tradename>
						<drug type="generic" refid="idelem4x22280">OLANZapine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2232">
				<sec_title>Action:</sec_title>
				<para>Bioconverted to 5-aminosalicylic acid, which decreases inflammation</para>
			</section>
			<section type="uses" id="sidelem4x2237">
				<sec_title>Uses:</sec_title>
				<para>Maintenance of remission of ulcerative colitis in patients intolerant to sulfasalazine</para>
			</section>
			<section type="contra" id="sidelem4x2242">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or salicylates</para>
				<section type="none" id="sidelem4x2247">
					<section type="none" id="sidelem4x2248">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;14 yr; impaired renal/hepatic function; severe allergy; bronchial asthma</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2253">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2261">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2261">
							<item>
								<label>•</label>
								<para> 500 mg bid, max 3 g/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2265">
					<section type="none" id="sidelem4x2266">
						<sec_title>Available forms:</sec_title>
						<para> Caps 250 mg</para>
					</section>
					<section type="none" id="sidelem4x2271">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2275">
								<item>
									<label>•</label>
									<para>Total daily dose evenly spaced to minimize GI intolerance; give with food</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2286">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2289">
					<section type="none" id="sidelem4x2290">
						<sec_title>CNS:</sec_title>
						<para> Headache, hallucinations, depression, vertigo, fatigue, dizziness</para>
					</section>
					<section type="none" id="sidelem4x2295">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, abdominal pain, <emphasis style="bold">hepatitis,</emphasis> diarrhea, bloating, pancreatitis</para>
					</section>
					<section type="none" id="sidelem4x2303">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, neutropenia, thrombocytopenia, agranulocytosis, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2310">
						<sec_title>INTEG:</sec_title>
						<para> Rash, dermatitis, urticaria</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2315">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Partially absorbed, peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, half-life 30-90 min (rectal), 2-15 hr (PO), excreted in urine as 5-aminosalicylic acid and metabolites, crosses placenta</para>
			</section>
			<section type="interactions" id="sidelem4x2326">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> azaTHIOprine toxicity—azaTHIOprine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—mercaptopurine, thioguanine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> PT, INR—warfarin</para>
				<section type="none" id="sidelem4x2341">
					<section type="none" id="sidelem4x2342">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2349">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2352">
					<section type="none" id="sidelem4x2353">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2361">
							<label>•</label>
							<sec_title>Colitis</sec_title>
							<para>
								<list id="lidelem4x2361">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Colitis:</emphasis> bowel pattern, number of stools, consistency, frequency, pain, mucus before treatment and periodically</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2366">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias: skin rash, fever, sore throat, bruising, bleeding, fatigue, joint pain (rare); CBC before treatment and periodically</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2374">
							<label>•</label>
							<sec_title>Allergic reaction</sec_title>
							<para>
								<list id="lidelem4x2374">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reaction:</emphasis> rash, dermatitis, urticaria, pruritus, dyspnea, bronchospasm; allergy to salicylates</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2378">
								<item>
									<label>•</label>
									<para>BUN, creatinine in those with renal disease; LFTs (liver disease)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2383">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2387">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fever, mucus in stools, decreased diarrhea, abdominal pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2393">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2397">
								<item>
									<label>•</label>
									<para>To report diarrhea, rash, bleeding, bruising, fever, hallucinations</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may cause dizziness; to avoid hazardous activities until reaction is known</para>
								</item>
								<item>
									<label>•</label>
									<para>To take even if feeling better; to take as directed; to take missed dose when remembered, but not to double</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active" ru="yes">
			<mono_name> omacetaxine</mono_name>
			<info>
				<pronunciation>(oh′ma-set-ax′een)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x24210">Synribo</tradename>
				</tradenames>
				<class type="func"> Antineoplastic-miscellaneous</class>
				<class type="chem"> Cephalotaxine ester (derived from the Evergreen tree: </class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="uses" id="sidelem4x2433">
				<sec_title>Uses:</sec_title>
				<para>Chronic or accelerated phase chronic myelogenous leukemia (CML) with resistance or/and intolerance to 2 or more tyrosine kinase inhibitors</para>
			</section>
			<section type="contra" id="sidelem4x2438">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity</para>
			</section>
			<section type="doses" id="sidelem4x2443">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2451">
					<label>•</label>
					<sec_title>
						<route>SUBCUT</route>
					</sec_title>
					<para>
						<list id="lidelem4x2451">
							<item>
								<label>•</label>
								<para>Adult:  1.25 mg/m<emphasis style="sup">2</emphasis> bid × 14 days every 28 days</para>
							</item>
						</list>
					</para>
				</section>
				<para>
					<list id="lidelem4x2460">
						<item>
							<para>
								<emphasis alert="nurse">
									<emphasis style="italic">Grade 4 neutropenia (absolute neutrophil count [ANC] &lt;0.5 × 10<emphasis style="sup">9</emphasis>/L) or grade 3 thrombocytopenia (platelet count &lt;50 × 10<emphasis style="sup">9</emphasis>/L):</emphasis> Do not start the next cycle until the ANC is ≥1 × 10<emphasis style="sup">9</emphasis>/L and platelets are ≥50 × 10<emphasis style="sup">9</emphasis>/L; when therapy is resumed, reduce the number of dosing days by 2 days/cycle (initial cycles, from 14 to 12 days; maintenance cycles, from 7 to 5 days)</emphasis>
							</para>
						</item>
					</list>
				</para>
			</section>
		</monograph>
<monograph id="12" status="active">
			<mono_name>omalizumab (Rx)</mono_name>
			<info>
				<pronunciation>(oh-mah-lye-zoo′mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x24840">Xolair</tradename>
				</tradenames>
				<class type="func"> Antiasthmatic</class>
				<class type="chem"> Monoclonal antibody</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x2494">
				<sec_title>Action:</sec_title>
				<para>Recombinant DNA-derived humanized IgG murine monoclonal antibody that selectively binds to IgE to limit the release of mediators in the allergic response</para>
			</section>
			<section type="uses" id="sidelem4x2499">
				<sec_title>Uses:</sec_title>
				<para>Moderate to severe persistent asthma</para>
				<section type="none" id="sidelem4x2504">
					<section type="none" id="sidelem4x2505">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Seasonal allergic rhinitis, food allergy</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2510">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to hamster protein</para>
				<para>
					<bbw>Hypersensitivity to this product</bbw>
				</para>
				<section type="none" id="sidelem4x2525">
					<section type="none" id="sidelem4x2526">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children &lt;12 yr, acute attacks of asthma, lymphoma, nephrotic disease, bronchospasm, neoplastic disease, status asthmaticus</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2531">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2539">
					<label>•</label>
					<sec_title>Adult/adolescent/child ≥12 yr<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x2539">
							<item>
								<label>•</label>
								<para> 150-375 mg × 2-4 wk; divide inj into 2 sites if dose &gt;150 mg; dose is adjusted based on IgE levels, significant changes in body weight</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2543">
					<section type="none" id="sidelem4x2544">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj, lyophilized 202.5 mg (150 mg/1.2 ml after reconstitution)</para>
					</section>
					<section type="none" id="sidelem4x2549">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2552">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x2556">
									<item>
										<label>•</label>
										<para>Reconstitute using 1.4 ml sterile water for inj (150 mg/1.2 ml or 125 mg/ml); gently swirl to dissolve; allow vial to stand and q5min gently swirl for 5-10 sec to dissolve; some vials may take ≥20 min; do not use if contents do not dissolve within 40 min; should be clear or slightly opalescent; use large-bore needle to withdraw medication; replace needle with small-bore needle</para>
									</item>
									<item>
										<label>•</label>
										<para>Given q2-4wk; product is viscous; if &gt;150 mg is given, divide into 2 sites; inj may take 5-10 sec to administer</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2567">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2570">
					<section type="none" id="sidelem4x2571">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Heart failure,</emphasis> cardiomyopathy, hypotension</para>
					</section>
					<section type="none" id="sidelem4x2579">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Serious systemic eosinophilia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2586">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, dermatitis, inj-site reactions, rash</para>
					</section>
					<section type="none" id="sidelem4x2591">
						<sec_title>MISC:</sec_title>
						<para> Earache, dizziness, fatigue, pain, <emphasis style="bold">malignancies</emphasis>, viral infections, <emphasis style="bold">anaphylaxis, thrombocytopenia,</emphasis> headache</para>
					</section>
					<section type="none" id="sidelem4x2602">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, fracture, leg, arm pain</para>
					</section>
					<section type="none" id="sidelem4x2608">
						<sec_title>RESP:</sec_title>
						<para> Sinusitis, upper respiratory infections, pharyngitis, pulmonary hypertension, <emphasis style="bold">bronchospasm</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2615">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Slowly absorbed, peak 7-8 days, half-life 26 days, degradation by liver, excretion in bile</para>
			</section>
			<section type="interactions" id="sidelem4x2620">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x2624">
						<item>
							<label>•</label>
							<para>Use cautiously with live virus vaccines</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x2630">
					<section type="none" id="sidelem4x2631">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> IgE</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2638">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2641">
					<section type="none" id="sidelem4x2642">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2650">
							<label>•</label>
							<sec_title>Asthma</sec_title>
							<para>
								<list id="lidelem4x2650">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Asthma:</emphasis> respiratory rate, rhythm, depth; auscultate lung fields bilaterally; notify prescriber of abnormalities; monitor pulmonary function tests; serum IgE (may increase and continue for 1 yr)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2657">
							<label>•</label>
							<sec_title>Inj-site reactions</sec_title>
							<para>
								<list id="lidelem4x2657">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Inj-site reactions:</emphasis> inflammation, edema, redness, warmth at site; may occur within 60 min of inj; may decrease with repeated dosing</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Anaphylaxis, allergic reactions:</emphasis> rash, urticaria, inability to breathe, edema of throat; product should be discontinued; have emergency equipment available; observe for 2 hr; reaction can occur ≤24 hr</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x2673">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2677">
								<item>
									<label>•</label>
									<para>Therapeutic response: ability to breathe more easily</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2683">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2687">
								<item>
									<label>•</label>
									<para>That improvement will not be immediate</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to stop taking or decrease current asthma medications unless instructed by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid live virus vaccines while taking this product</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>To report signs of allergic reaction immediately, can be life-threatening</bbw>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active">
			<mono_name>omeprazole (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(oh-mep′ray-zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x27212">
						<country code="CAN">Losec </country>
					</tradename>
					<tradename id="tnidelem4x27211">PriLOSEC</tradename>
					<tradename id="tnidelem4x27210">PriLOSEC OTC</tradename>
				</tradenames>
				<class type="func"> Antiulcer, proton pump inhibitor</class>
				<class type="chem"> Benzimidazole</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2734">
				<para>
					<confusion>
						<tradename id="tnidelem4x27340">PriLOSEC</tradename>
						<drug type="generic" refid="idelem4x27340">Prinivil/PROzac/predniSONE</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2738">
				<sec_title>Action:</sec_title>
				<para>Suppresses gastric secretion by inhibiting hydrogen/potassium ATPase enzyme system in gastric parietal cells; characterized as gastric acid pump inhibitor because it blocks the final step of acid production</para>
			</section>
			<section type="uses" id="sidelem4x2743">
				<sec_title>Uses:</sec_title>
				<para>Gastroesophageal reflux disease (GERD), severe erosive esophagitis, poorly responsive systemic GERD, pathologic hypersecretory conditions (Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas); treatment of active duodenal ulcers with/without antiinfectives for <emphasis style="italic">Helicobacter pylori</emphasis></para>
				<section type="none" id="sidelem4x2750">
					<section type="none" id="sidelem4x2751">
						<sec_title>Unlabeled uses:</sec_title>
						<para> NSAID-induced ulcer prophylaxis, stress gastritis prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2756">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x2761">
					<section type="none" id="sidelem4x2762">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2767">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2770">
					<section type="none" id="sidelem4x2771">
						<sec_title>Active duodenal ulcers</sec_title>
						<section type="none" id="sidelem4x2779">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2779">
									<item>
										<label>•</label>
										<para> 20 mg/day × 4-8 wk; associated with <emphasis style="italic">H. pylori</emphasis> 40 mg q <emphasis style="smallcaps">am</emphasis> and clarithromycin 500 mg tid on days 1-14, then 20 mg/day on days 15-28</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2789">
						<sec_title>Severe erosive esophagitis/poorly responsive GERD</sec_title>
						<section type="none" id="sidelem4x2797">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2797">
									<item>
										<label>•</label>
										<para> (del rel cap/del rel susp) 20 mg/day × 4-8 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2802">
						<sec_title>Pathologic hypersecretory conditions</sec_title>
						<section type="none" id="sidelem4x2810">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2810">
									<item>
										<label>•</label>
										<para> 60 mg/day; may increase to 120 mg tid; daily doses &gt;80 mg should be divided</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2814">
						<sec_title>Gastric ulcer</sec_title>
						<section type="none" id="sidelem4x2822">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2822">
									<item>
										<label>•</label>
										<para> 40 mg/day 4-8 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2829">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2829">
									<item>
										<label>•</label>
										<para> ≤20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2833">
						<sec_title>Heartburn (OTC)</sec_title>
						<section type="none" id="sidelem4x2841">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2841">
									<item>
										<label>•</label>
										<para> 1 del rel tab (20 mg)/day before <emphasis style="smallcaps">am</emphasis> meal with glass of water × 14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2848">
						<sec_title>Available forms:</sec_title>
						<para> Del rel caps 10, 20, 40 mg; del rel tabs 20 mg; granules for oral susp 2.5, 10 mg (del rel)</para>
					</section>
					<section type="none" id="sidelem4x2853">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2858">
								<item>
									<label>•</label>
									<para>Swallow caps whole; do not crush or chew; caps may be opened and sprinkled over applesauce</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2863">
								<item>
									<label>•</label>
									<para>Before eating, usually in the <emphasis style="smallcaps">am</emphasis>, separate with other medications</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2874">
							<label>•</label>
							<sec_title>Oral susp powder</sec_title>
							<para>
								<list id="lidelem4x2874">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral susp powder:</emphasis> give on empty stomach ≥1 hr before food; if there is NG or enteral feeding tube, do not feed 3 hr before or 1 hr after giving product: contents of packet should be mixed with 1-2 tbsp water; add 20 ml water for NG tube; for oral, stir well, drink, add more water, and drink</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2878">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2881">
					<section type="none" id="sidelem4x2882">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness, asthenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2889">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, abdominal pain, vomiting, nausea, constipation, flatulence, acid regurgitation,</emphasis> abdominal swelling, anorexia, irritable colon, esophageal candidiasis, dry mouth, <emphasis style="bold">hepatic failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2899">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> dry skin, urticaria, pruritus, alopecia</para>
					</section>
					<section type="none" id="sidelem4x2907">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Back pain,</emphasis> fever, fatigue, malaise</para>
					</section>
					<section type="none" id="sidelem4x2915">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Upper respiratory infections, cough,</emphasis> epistaxis, <emphasis style="bold">pneumonia</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2925">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailabity 30%-40%; peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-3<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; half-life <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr; protein binding 95%; eliminated in urine as metabolites and in feces; in geriatric patients, elimination rate decreased, bioavailability increased; metabolized by CYP2C19 enzyme system</para>
			</section>
			<section type="interactions" id="sidelem4x2948">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—warfarin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> serum levels of diazepam, phenytoin, flurazepam, triazolam, cycloSPORINE, disulfiram, digoxin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of iron salts, ketoconazole, cyanocobalamin, calcium carbonate, ampicillin, indinavir, gefitinib</para>
				<section type="none" id="sidelem4x2963">
					<section type="none" id="sidelem4x2964">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> alk phos, AST, ALT, bilirubin, gastrin</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2971">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2974">
					<section type="none" id="sidelem4x2975">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2983">
							<label>•</label>
							<sec_title>GI system</sec_title>
							<para>
								<list id="lidelem4x2983">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">GI system:</emphasis> bowel sounds q8hr, abdomen for pain, swelling, anorexia, blood in stools</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2990">
							<label>•</label>
							<sec_title>Electrolyte imbalances</sec_title>
							<para>
								<list id="lidelem4x2990">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Electrolyte imbalances:</emphasis> hyponatremia; hypomagnesemia in patients using product (3 mo-1 yr); if hypomagnesemia occurs, use of magnesium supplements may be sufficient; if severe, discontinue product</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2997">
							<label>•</label>
							<sec_title>Hepatic enzymes</sec_title>
							<para>
								<list id="lidelem4x2997">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hepatic enzymes:</emphasis> AST, ALT, alk phos during treatment; <emphasis style="bold">blood studies:</emphasis> CBC, differential during treatment, blood dyscrasias may occur; vit B<emphasis style="inf">12</emphasis> in long-term treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3007">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3011">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of epigastric pain, swelling, fullness, bleeding: decreased GERD, esophagitis symptoms</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3017">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x3025">
							<label>•</label>
							<sec_title>
								<route>To report severe diarrhea; black, tarry stools; abdominal cramps/pain; or continuing headache; product may have to be discontinued</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3028">
								<item>
									<label>•</label>
									<para>That, if diabetic, hypoglycemia may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3033">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities because dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3038">
								<item>
									<label>•</label>
									<para>To avoid alcohol, salicylates, NSAIDs; may cause GI irritation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3043">
								<item>
									<label>•</label>
									<para>To take as directed, even if feeling better; to take missed dose as soon as remembered; not to double; PriLOSEC OTC takes up to 4 days for full effect</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active">
			<mono_name>ondansetron (Rx)</mono_name>
			<info>
				<pronunciation>(on-dan-seh′tron)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x30542">Zofran</tradename>
					<tradename id="tnidelem4x30541">Zofran ODT</tradename>
					<tradename id="tnidelem4x30540">Zuplenz</tradename>
				</tradenames>
				<class type="func"> Antiemetic</class>
				<class type="chem"> 5-HT receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3067">
				<para>
					<confusion>
						<tradename id="tnidelem4x30670">Zofran</tradename>
						<drug type="generic" refid="idelem4x30670">Zantac</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3071">
				<sec_title>Action:</sec_title>
				<para>Prevents nausea, vomiting by blocking serotonin peripherally, centrally, and in the small intestine</para>
			</section>
			<section type="uses" id="sidelem4x3076">
				<sec_title>Uses:</sec_title>
				<para>Prevention of nausea, vomiting associated with cancer chemotherapy, radiotherapy; prevention of postoperative nausea, vomiting</para>
				<section type="none" id="sidelem4x3081">
					<section type="none" id="sidelem4x3082">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Pruritus (rectal use), alcoholism, hyperemesis gravidarum</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3087">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity; phenylketonuric hypersensitivity (oral disintegrating tab), torsades de pointes</para>
				<section type="none" id="sidelem4x3092">
					<section type="none" id="sidelem4x3093">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, granisetron hypersensitivity, QT prolongation, torsades de pointes</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3098">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3101">
					<section type="none" id="sidelem4x3102">
						<sec_title>Prevention of nausea/vomiting (cancer chemotherapy)</sec_title>
						<section type="none" id="sidelem4x3110">
							<label>•</label>
							<sec_title>Adult and child 4-18 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3110">
									<item>
										<label>•</label>
										<para> 0.15 mg/kg infused over 15 min given 30 min before start of cancer chemotherapy, max 16 mg/dose; 0.15 mg/kg given 4 hr and 8 hr after 1st dose or 16 mg as single dose; dilute in 50 ml of D<emphasis style="inf">5</emphasis> or 0.9% NaCl before giving;  (unlabeled) 16 mg/day 2 hr before chemotherapy;  8 mg <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr before chemotherapy, repeat 4, 8 hr after 1st dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3132">
							<label>•</label>
							<sec_title>Child ≥4 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3132">
									<item>
										<label>•</label>
										<para> 4 mg tid, first dose <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr before chemotherapy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3142">
						<sec_title>Prevention of nausea/vomiting (radiotherapy)</sec_title>
						<section type="none" id="sidelem4x3150">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3150">
									<item>
										<label>•</label>
										<para> 8 mg tid, may repeat q8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3154">
						<sec_title>Prevention of postoperative nausea/vomiting</sec_title>
						<section type="none" id="sidelem4x3162">
							<label>•</label>
							<sec_title>Adult<route> IV/IM</route></sec_title>
							<para>
								<list id="lidelem4x3162">
									<item>
										<label>•</label>
										<para> 4 mg undiluted over &gt;30 sec before induction of anesthesia</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3169">
							<label>•</label>
							<sec_title>Child 2-12 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3169">
									<item>
										<label>•</label>
										<para> 0.1 mg/kg (≤40 kg);  4 mg (≥40 kg), give over ≥30 sec</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3176">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x3184">
							<label>•</label>
							<sec_title>Adult<route> PO/IM/IV max dose 8 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3187">
						<sec_title>Hyperemesis gravidarum (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3195">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x3195">
									<item>
										<label>•</label>
										<para> 4-8 mg bid-tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3201">
						<sec_title>Pruritus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3209">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3209">
									<item>
										<label>•</label>
										<para> 8 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3213">
						<sec_title>Alcoholism (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3221">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3221">
									<item>
										<label>•</label>
										<para> 4 mcg/kg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3225">
						<sec_title>Available forms:</sec_title>
						<para> Inj 2 mg/ml, 32 mg/50 ml (premixed); tabs 4, 8 mg; oral sol 4 mg/5 ml; oral disintegrating tabs 4, 8 mg; oral dissolving film 4, 8 mg</para>
					</section>
					<section type="none" id="sidelem4x3230">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3233">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x3241">
								<label>•</label>
								<sec_title>Oral disintegrating tab</sec_title>
								<para>
									<list id="lidelem4x3241">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral disintegrating tab:</emphasis> do not push through foil; gently remove; immediately place on tongue to dissolve; swallow with saliva</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x3248">
								<label>•</label>
								<sec_title>Oral dissolving film</sec_title>
								<para>
									<list id="lidelem4x3248">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral dissolving film:</emphasis> fold pouch along dotted line to expose tear notch; while folded, tear and remove film; place film on tongue until dissolved; swallow after dissolved; to reach desired dose, administer successive films, allowing each to dissolve before using another</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x3252">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x3256">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate or discoloration</para>
									</item>
									<item>
										<label>•</label>
										<para>May give 4 mg undiluted IM; inject deeply in large muscle mass; aspirate</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3267">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x3272">
									<item>
										<label>•</label>
										<para>Check for discoloration or particulate; if particulate is present, shake to dissolve</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x3277">
									<item>
										<label>•</label>
										<para>After diluting single dose in 50 ml NS or D<emphasis style="inf">5</emphasis>W, 0.45% NaCl or NS; give over 15 min</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x3288">
								<label>•</label>
								<sec_title>
									<route>Do not use IV 32 mg/dose in chemotherapy nausea/vomiting due to QT prolongation, max 16 mg/dose (adult)</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x3291">
									<item>
										<label>•</label>
										<para>Store at room temperature for 48 hr after dilution</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Aldesleukin, amifostine, amikacin, aztreonam, bleomycin, CARBOplatin, carmustine, ceFAZolin, cefmetazole, cefotaxime, cefOXitin, cefTAZidime, ceftizoxime, cefuroxime, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, cladribine, clindamycin, cyclophosphamide, cytarabine, dacarbazine, DACTINomycin, DAUNOrubicin, dexamethasone, diphenhydrAMINE, DOPamine, DOXOrubicin, DOXOrubicin liposome, doxycycline, droperidol, etoposide, famotidine, filgrastim, floxuridine, fluconazole, fludarabine, gallium, gentamicin, haloperidol, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, ifosfamide, imipenem-cilastatin, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, mesna, methotrexate, metoclopramide, miconazole, mitoMYcin, mitoXANtrone, morphine, PACLitaxel, pentostatin, piperacillin/tazobactam, potassium chloride, prochlorperazine, promethazine, ranitidine, remifentanil, streptozocin, teniposide, thiotepa, ticarcillin, ticarcillin-clavulanate, vancomycin, vinBLAStine, vinCRIStine, vinorelbine, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3302">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3305">
					<section type="none" id="sidelem4x3306">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness, drowsiness, fatigue, EPS</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3313">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, constipation,</emphasis> abdominal pain, dry mouth</para>
					</section>
					<section type="none" id="sidelem4x3321">
						<sec_title>MISC:</sec_title>
						<para> Rash, <emphasis style="bold">bronchospasm</emphasis> (rare), <emphasis style="italic">musculoskeletal pain, wound problems, shivering, fever, hypoxia, urinary retention</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3331">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x3334">
					<section type="none" id="sidelem4x3335">
						<sec_title>IV:</sec_title>
						<para> Mean elimination half-life 3.5-4.7 hr, plasma protein binding 70%-76%, extensively metabolized in the liver, excreted 45%-60% in urine</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x3340">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: unconsciousness, hypotension—apomorphine, do not use together</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—other products that prolong QT</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> ondansetron effect—rifampin, carBAMazepine, phenytoin</para>
				<section type="none" id="sidelem4x3353">
					<section type="none" id="sidelem4x3354">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3361">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3364">
					<section type="none" id="sidelem4x3365">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3370">
								<item>
									<label>•</label>
									<para>Absence of nausea, vomiting during chemotherapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3375">
								<item>
									<label>•</label>
									<para>Hypersensitivity reaction: rash, bronchospasm (rare)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3383">
							<label>•</label>
							<sec_title>EPS</sec_title>
							<para>
								<list id="lidelem4x3383">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">EPS:</emphasis> shuffling gait, tremors, grimacing, rigidity periodically</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3390">
							<label>•</label>
							<sec_title>QT prolongation<route> monitoring ECG in those with cardiac disease or receiving other products that increase QT</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3393">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3397">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of nausea, vomiting during cancer chemotherapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3403">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3407">
								<item>
									<label>•</label>
									<para>To report diarrhea, constipation, rash, changes in respirations, or discomfort at insertion site</para>
								</item>
								<item>
									<label>•</label>
									<para>Headache requiring analgesic is common</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active">
			<mono_name>oritavancin</mono_name>
			<info>
				<pronunciation>(or-it′a-van′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x34230">Orbactiv</tradename>
				</tradenames>
				<class type="func"> Antiinfective agents</class>
				<class type="chem"> Glycopeptides</class>
			</info>
			<section type="actions" id="sidelem4x3433">
				<sec_title>Action:</sec_title>
				<para> Inhibits bacterial cell-wall biosynthesis by preventing transglycosylation (polymerization) by binding to precursors, as well as by preventing cross-linking by binding to the peptide bridging segments of the cell wall, also disrupts the bacterial cell membrane integrity, resulting in depolarization, increased permeability, and eventual cell death</para>
			</section>
			<section type="uses" id="sidelem4x3438">
				<sec_title>Uses:</sec_title>
				<para> <emphasis style="italic">Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus</emphasis> (MRSA), <emphasis style="italic">Staphylococcus aureus</emphasis> (MSSA), <emphasis style="italic">Streptococcus agalactiae</emphasis> (group B streptococci), <emphasis style="italic">Streptococcus anginosus, Streptococcus constellatus, Streptococcus dysgalactiae, Streptococcus intermedius, Streptococcus pyogenes</emphasis> (group A β-hemolytic streptococci); treatment of acute bacterial skin and skin structure infections (ABSSSI) due to gram-positive organisms, including cellulitis/erysipelas, major cutaneous abscesses, and wound infections</para>
			</section>
			<section type="contra" id="sidelem4x3457">
				<sec_title>Contraindications:</sec_title>
				<para> Hypersensitivity</para>
				<section type="none" id="sidelem4x3462">
					<section type="none" id="sidelem4x3463">
						<sec_title>Precautions:</sec_title>
						<para> Anticoagulant therapy, antimicrobial resistance, breastfeeding, colitis, diarrhea, inflammatory bowel disease, infusion reactions, pregnancy, pseudomembranous colitis, vancomycin hypersensitivity, viral infection</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3468">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3476">
					<label>•</label>
					<sec_title>Adults<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x3476">
							<item>
								<label>•</label>
								<para> 1200 mg once</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3480">
					<section type="none" id="sidelem4x3481">
						<sec_title>Available forms:</sec_title>
						<para> Powder for injection: 400 mg</para>
					</section>
					<section type="none" id="sidelem4x3486">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3491">
								<item>
									<label>•</label>
									<para>Visually inspect for particulate matter and discoloration beforehand, the reconstituted solution is clear, colorless to pale yellow</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3499">
							<label>•</label>
							<sec_title>Reconstitution</sec_title>
							<para>
								<list id="lidelem4x3499">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Reconstitution:</emphasis> Reconstitute each 400-mg vial with 40 ml sterile water for injection. Three vials are necessary for a single dose, gently swirl until dissolved</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3506">
							<label>•</label>
							<sec_title>
								<route>Dilution</route>
							</sec_title>
							<para>
								<list id="lidelem4x3506">
									<item>
										<label>•</label>
										<para>: Withdraw and discard 120 ml from a 1000-ml intravenous bag of D<emphasis style="inf">5</emphasis>W, transfer 40 ml solution from each of the 3 reconstituted vials to the D<emphasis style="inf">5</emphasis>W IV bag (1.2 mg/mg)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3519">
							<label>•</label>
							<sec_title>Storage</sec_title>
							<para>
								<list id="lidelem4x3519">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Storage:</emphasis> Refrigerate or store at room temperature. The combined storage time (from reconstitution to dilution) and 3-hour infusion time should not exceed 6 hr at room temperature or 12 hr if refrigerated</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3523">
							<sec_title>Intermittent IV INFUSION</sec_title>
							<para>
								<list id="lidelem4x3527">
									<item>
										<label>•</label>
										<para>Infuse over 3 hr, do not infuse with other medications or electrolytes, do not use saline-based solution</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3533">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3536">
					<section type="none" id="sidelem4x3537">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, flushing, headache</para>
					</section>
					<section type="none" id="sidelem4x3542">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Sinus tachycardia,</emphasis> phlebitis</para>
					</section>
					<section type="none" id="sidelem4x3550">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x3555">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, eosinophilia</para>
					</section>
					<section type="none" id="sidelem4x3560">
						<sec_title>MS:</sec_title>
						<para> Myalgia, osteomyelitis</para>
					</section>
					<section type="none" id="sidelem4x3565">
						<sec_title>INTEG:</sec_title>
						<para> Rash, vasculitis, pruritus, <emphasis style="bold">angioedema,</emphasis> infusion-related reaction</para>
					</section>
					<section type="none" id="sidelem4x3573">
						<sec_title>MISC:</sec_title>
						<para> Wheezing, <emphasis style="bold">bronchospasm</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3580">
				<sec_title>Pharmacokinetics</sec_title>
				<para>85% protein binding, terminal half-life 245 hr</para>
			</section>
			<section type="interactions" id="sidelem4x3585">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x3588">
					<section type="none" id="sidelem4x3589">
						<sec_title>Increase:</sec_title>
						<para> <emphasis style="bold">toxicity—</emphasis>products metabolized by CYP2D6 CYP3A4</para>
					</section>
					<section type="none" id="sidelem4x3597">
						<sec_title>Drug/lab test</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x3601">
						<sec_title>Increase:</sec_title>
						<para> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3606">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3609">
					<section type="none" id="sidelem4x3610">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3614">
								<item>
									<label>•</label>
									<para>CBC and differential</para>
								</item>
								<item>
									<label>•</label>
									<para>For diarrhea, bloody stools, cramping</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3625">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3629">
								<item>
									<label>•</label>
									<para>Therapeutic response: resolution of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3635">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3639">
								<item>
									<label>•</label>
									<para>Reason for product, expected result</para>
								</item>
								<item>
									<label>•</label>
									<para>Used only once to resolve infection</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16" status="active">
			<mono_name>orlistat (Rx, <emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(or′lih-stat)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x36581">Alli</tradename>
					<tradename id="tnidelem4x36580">Xenical</tradename>
				</tradenames>
				<class type="func"> Weight-control agent</class>
				<class type="chem"> Lipase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3668">
				<para>
					<confusion>
						<tradename id="tnidelem4x36680">Xenical</tradename>
						<drug type="generic" refid="idelem4x36680">Xeloda</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3672">
				<sec_title>Action:</sec_title>
				<para>Inhibits the absorption of dietary fats</para>
			</section>
			<section type="uses" id="sidelem4x3677">
				<sec_title>Uses:</sec_title>
				<para>Obesity management</para>
			</section>
			<section type="contra" id="sidelem4x3682">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, chronic m alabsorption syndrome, cholestasis</para>
				<section type="none" id="sidelem4x3687">
					<section type="none" id="sidelem4x3688">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="X">X</preg>), children, hypothyroidism, other organic causes of obesity, anorexia nervosa, bulimia, nephrolithiasis, GI disease, diabetes, fat-soluble vitamin deficiency, breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3693">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3701">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3701">
							<item>
								<label>•</label>
								<para> (Alli) 60 mg, (Xenical) 120 mg tid with each main meal containing fat, max 360 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3705">
					<section type="none" id="sidelem4x3706">
						<sec_title>Available forms:</sec_title>
						<para> Caps (Alli) 60 mg, (Xenical) 120 mg</para>
					</section>
					<section type="none" id="sidelem4x3712">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3716">
								<item>
									<label>•</label>
									<para>For obesity only if patient on weight-reduction program that includes dietary changes, exercise; patient should be on a diet with 30% of calories from fat; omit dose of orlistat if meal contains no fat</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3722">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3725">
					<section type="none" id="sidelem4x3726">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Insomnia,</emphasis> depression, anxiety, dizziness, headache, fatigue</para>
					</section>
					<section type="none" id="sidelem4x3734">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, fecal incontinence, frequent defecation,</emphasis> nausea, vomiting, abdominal pain, infectious diarrhea, rectal pain, tooth disorder, hypovitaminosis, <emphasis style="bold">hepatic failure, hepatitis, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3744">
						<sec_title>GU:</sec_title>
						<para> UTI, vaginitis, menstrual irregularity</para>
					</section>
					<section type="none" id="sidelem4x3749">
						<sec_title>INTEG:</sec_title>
						<para> Dry skin, rash</para>
					</section>
					<section type="none" id="sidelem4x3754">
						<sec_title>MS:</sec_title>
						<para> Back pain, arthritis, myalgia, tendinitis</para>
					</section>
					<section type="none" id="sidelem4x3759">
						<sec_title>RESP:</sec_title>
						<para> Influenza, URI</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3764">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Minimal absorption, peak 8 hr, 99% protein binding, excretion in feces, half-life 1-2 hr</para>
			</section>
			<section type="interactions" id="sidelem4x3769">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> lipid-lowering effect—pravastatin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—fat-soluble vitamins (A, D, E, K), cycloSPORINE</para>
			</section>
			<section type="considerations" id="sidelem4x3784">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3787">
					<section type="none" id="sidelem4x3788">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3796">
							<label>•</label>
							<sec_title>Weight status</sec_title>
							<para>
								<list id="lidelem4x3796">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Weight status:</emphasis> before starting therapy, obtain testing to rule out physiologic reactions for weight, obtain thyroid testing, BMI, glucose; weight weekly; diabetic patients may need reduction in oral hypoglycemics</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3800">
								<item>
									<label>•</label>
									<para>For misuse in certain populations (anorexia nervosa, bulimia)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3806">
								<item>
									<para>
										<emphasis alert="nurse">Hepatotoxicity/pancreatitis: jaundice, weakness, abdominal pain (rare)</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3811">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3815">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in weight</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3821">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3826">
								<item>
									<label>•</label>
									<para>That 60-mg cap can be obtained OTC; 60 mg tid is highest OTC dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3831">
								<item>
									<label>•</label>
									<para>That safety and effectiveness beyond 2 yr have not been determined</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3836">
								<item>
									<label>•</label>
									<para>To read patient information sheet; to discuss unpleasant GI side effects</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3841">
								<item>
									<label>•</label>
									<para>To take multivitamin containing fat-soluble vitamins 2 hr before or after orlistat; that psyllium taken with each dose or at bedtime may decrease GI symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3846">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on medication; to discuss unpleasant side effects</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3854">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected pregnancy (X); if breastfeeding take proper fat-soluble vitamins</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3858">
								<item>
									<para>
										<emphasis alert="nurse">Hepatotoxicity/pancreatitis: yellowing of skin, eyes; dark urine; weakness; abdominal pain</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active">
			<mono_name>oseltamivir (Rx)</mono_name>
			<info>
				<pronunciation>(oss-el-tam′ih-veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x38680">Tamiflu</tradename>
				</tradenames>
				<class type="func"> Antiviral</class>
				<class type="chem"> Neuramidase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3878">
				<sec_title>Action:</sec_title>
				<para>Inhibits influenza virus neuraminidase with possible alteration of virus particle aggregation and release</para>
			</section>
			<section type="uses" id="sidelem4x3883">
				<sec_title>Uses:</sec_title>
				<para>Prevention and treatment of influenza type A or B</para>
				<section type="none" id="sidelem4x3888">
					<section type="none" id="sidelem4x3889">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Avian flu (H5N1), avian influenzae A (H5N1), swine flu (H1N1), encephalitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3894">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x3899">
					<section type="none" id="sidelem4x3900">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), neonates, breastfeeding, infants, children, geriatric patients, renal/hepatic/pulmonary/cardiac disease, psychosis, viral infection</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3905">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3908">
					<section type="none" id="sidelem4x3909">
						<sec_title>Treatment of influenza</sec_title>
						<section type="none" id="sidelem4x3917">
							<label>•</label>
							<sec_title>Adult/child &gt;40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3917">
									<item>
										<label>•</label>
										<para> 75 mg bid × 5 days, begin treatment within 2 days of onset of symptoms</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3925">
							<label>•</label>
							<sec_title>Child 23-40 kg and ≥1 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3925">
									<item>
										<label>•</label>
										<para> 60 mg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3932">
							<label>•</label>
							<sec_title>Child 15-23 kg and ≥1 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3932">
									<item>
										<label>•</label>
										<para> 45 mg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3939">
							<label>•</label>
							<sec_title>Child ≤15 kg and ≥1 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3939">
									<item>
										<label>•</label>
										<para> 30 mg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3946">
							<label>•</label>
							<sec_title>Neonates ≥14 days, infants<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3946">
									<item>
										<label>•</label>
										<para> 3 mg/kg/dose bid × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3950">
						<sec_title>Prevention of influenza</sec_title>
						<section type="none" id="sidelem4x3958">
							<label>•</label>
							<sec_title>Adult/child ≥13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3958">
									<item>
										<label>•</label>
										<para> 75 mg/day × ≥10 days; begin treatment within 2 days of contact, max use 6 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3962">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x3970">
							<label>•</label>
							<sec_title>Adult<route> PO Treatment</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3973">
						<sec_title>H1N1 influenzae A virus (swine flu) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3981">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3981">
									<item>
										<label>•</label>
										<para> 75 mg bid × 5 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3988">
							<label>•</label>
							<sec_title>Adolescent/child 24-40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3988">
									<item>
										<label>•</label>
										<para> 60 mg bid × 5 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3995">
							<label>•</label>
							<sec_title>Child &gt;1 yr and 15-23 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3995">
									<item>
										<label>•</label>
										<para> 45 mg bid × 5 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4002">
							<label>•</label>
							<sec_title>Child &gt;1 yr and ≤15 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4002">
									<item>
										<label>•</label>
										<para> 30 mg bid × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4006">
						<sec_title>Available forms:</sec_title>
						<para> Caps 30, 45, 75 mg; powder for oral susp 6 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x4011">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4016">
								<item>
									<label>•</label>
									<para>Within 2 days of symptoms of influenza; continue for 5 days</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4021">
								<item>
									<label>•</label>
									<para>At least 4 hr before bedtime to prevent insomnia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4026">
								<item>
									<label>•</label>
									<para>Without regard to food; give with food for GI upset</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4031">
								<item>
									<label>•</label>
									<para>Take with full glass of water</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4036">
								<item>
									<label>•</label>
									<para>Store in tight, dry container</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4044">
							<label>•</label>
							<sec_title>Oral susp</sec_title>
							<para>
								<list id="lidelem4x4044">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral susp:</emphasis> 6 mg/ml concentration, take care to administer correct dose; loosen powder from side of bottle, add 55 ml, shake well (6 mg/ml), remove child-resistant cap, push bottle adapter into neck of bottle, close tightly with child-resistant cap to ensure sealing, use within 17 days of preparation when refrigerated or within 10 days at room temperature, write expiration date on bottle, shake well before use, use oral syringe provided but only with markings for 30, 45, 60 mg, confirm that dosing instructions are in same units as syringe provided</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4048">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4051">
					<section type="none" id="sidelem4x4052">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis> fatigue, <emphasis style="italic">insomnia,</emphasis><emphasis style="bold">seizures,</emphasis> delirium, <emphasis style="bold">self-injury (children)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4067">
						<sec_title>ENDO:</sec_title>
						<para> Hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x4072">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> diarrhea, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x4080">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4087">
						<sec_title>RESP:</sec_title>
						<para> Cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4092">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed, protein binding 40%-45%, converted to oseltamivir carboxylate (active form), active forms half-life 1-3 hr, metabolite 6-10 hr, excreted in urine (99%), protein binding 3%</para>
			</section>
			<section type="interactions" id="sidelem4x4097">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x4101">
						<item>
							<label>•</label>
							<para>Avoid use with H1N1 virus vaccine, intranasal influenzae vaccine</para>
						</item>
					</list>
				</para>
			</section>
			<section type="considerations" id="sidelem4x4107">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4110">
					<section type="none" id="sidelem4x4111">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4116">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4124">
							<label>•</label>
							<sec_title>Influenza</sec_title>
							<para>
								<list id="lidelem4x4124">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Influenza:</emphasis> fever, fatigue, sore throat, headache, muscle soreness, aches</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4128">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4132">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fever, malaise, cough, dyspnea in infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4138">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4143">
								<item>
									<label>•</label>
									<para>About aspects of product therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4148">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4153">
								<item>
									<label>•</label>
									<para>To take as soon as symptoms appear; to take full course even if feeling better</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4158">
								<item>
									<label>•</label>
									<para>To take missed dose as soon as remembered if within 2 hr of next dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4164">
								<item>
									<para>
										<emphasis alert="nurse">To stop immediately; to report to prescriber skin rash, delirium, psychosis, hallucinations (child)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4169">
								<item>
									<label>•</label>
									<para>That this product should not be substituted for flu shot</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4174">
								<item>
									<label>•</label>
									<para>Will not treat the common cold</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4179">
								<item>
									<label>•</label>
									<para>To avoid other products unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active" ha="yes">
			<mono_name> oxaliplatin (Rx)</mono_name>
			<info>
				<pronunciation>(ox-al-i′plat-in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x41920">Eloxatin</tradename>
				</tradenames>
				<class type="func"> Antineoplastic</class>
				<class type="chem"> 3rd-generation platinum analog</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x4202">
				<sec_title>Action:</sec_title>
				<para>Forms crosslinks, thereby inhibiting DNA replication and transcription; not specific to cell cycle</para>
			</section>
			<section type="uses" id="sidelem4x4207">
				<sec_title>Uses:</sec_title>
				<para>Metastatic carcinoma of the colon or rectum in combination with 5-FU/leucovorin</para>
				<section type="none" id="sidelem4x4212">
					<section type="none" id="sidelem4x4213">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Relapsed or refractory non-Hodgkin’s lymphoma; advanced ovarian cancer; breast, head/neck, testicular, pancreatic, gastric cancer; mesothelioma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4218">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, radiation therapy or chemotherapy within 1 mo, thrombocytopenia, smallpox vaccination</para>
				<para>
					<bbw>Hypersensitivity to this product or other platinum products</bbw>
				</para>
				<section type="none" id="sidelem4x4233">
					<section type="none" id="sidelem4x4234">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, pneumococcus vaccination, renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4239">
				<sec_title>Dosage and routes</sec_title>
				<para>Dosage protocols may vary</para>
				<section type="none" id="sidelem4x4244">
					<section type="none" id="sidelem4x4245">
						<sec_title>Colorectal cancer</sec_title>
						<section type="none" id="sidelem4x4253">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x4253">
									<item>
										<label>•</label>
										<para>
											<emphasis style="italic">Day 1:</emphasis> oxaliplatin 85 mg/m<emphasis style="sup">2</emphasis> in 250-500 ml D<emphasis style="inf">5</emphasis>W and leucovorin 200 mg/m<emphasis style="sup">2</emphasis> in D<emphasis style="inf">5</emphasis>W; give both over 2 hr at the same time in separate bags using a <emphasis style="sans-serif">Y</emphasis>-line, followed by 5-FU 400 mg/m<emphasis style="sup">2</emphasis> over 2-4 min, then 5-FU 600 mg/m<emphasis style="sup">2</emphasis> in 500 ml D<emphasis style="inf">5</emphasis>W as a 22-hr <emphasis style="italic">day 2:</emphasis> leucovorin 200 mg/m<emphasis style="sup">2</emphasis> over 2 hr, then 5-FU 400 mg/m<emphasis style="sup">2</emphasis> over 2-4 min, then 5-FU 600 mg/m<emphasis style="sup">2</emphasis> in 500 ml D<emphasis style="inf">5</emphasis>W as a 22-hr  repeat cycle q2wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4313">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x4321">
							<label>•</label>
							<sec_title>Adult<route> IV CCr &lt;30 ml/min, reduce starting dose to 65 mg/m2</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4326">
						<sec_title>Advanced ovarian cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4334">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4334">
									<item>
										<label>•</label>
										<para> 130 mg/m<emphasis style="sup">2</emphasis> q3wk as a single agent in those previously treated</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4341">
						<sec_title>Advanced breast cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4349">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4349">
									<item>
										<label>•</label>
										<para> 130 mg/m<emphasis style="sup">2</emphasis> on day 1 plus 5-fluorouracil (1000 mg/m<emphasis style="sup">2</emphasis> days 1-4) q3wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4361">
						<sec_title>Pancreatic cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4369">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4369">
									<item>
										<label>•</label>
										<para> 100 mg/m<emphasis style="sup">2</emphasis> on day 2, with gemcitabine 1000 mg/m<emphasis style="sup">2</emphasis> on day 1, repeat q2wk; 625 mg/m<emphasis style="sup">2</emphasis> bid throughout treatment or fluorouracil 200 mg/m<emphasis style="sup">2</emphasis>/day throughout treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4385">
						<sec_title>Gastric cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4393">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4393">
									<item>
										<label>•</label>
										<para> 130 mg/m<emphasis style="sup">2</emphasis> over 2 hr on day 1 with epirubic 50 mg/m<emphasis style="sup">2</emphasis> and capecitabine</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4403">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 50, 100-mg single-use vials (5 mg/ml); solution for inj 50 mg/10 ml, 100 mg/20 ml, 200 mg/40 ml</para>
					</section>
					<section type="none" id="sidelem4x4408">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4411">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x4416">
									<item>
										<label>•</label>
										<para>Premedicate with antiemetics including 5HT<emphasis style="inf">3</emphasis> blockers, with or without dexamethasone; prehydration not needed</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x4424">
									<item>
										<label>•</label>
										<para>Do not reconstitute or dilute with sodium chloride or any chloride-containing sol; do not use aluminum equipment during any preparation or administration; will degrade platinum; do not refrigerate unopened powder or sol; do not freeze; protect from light</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x4429">
									<item>
										<label>•</label>
										<para>Use cytotoxic handling procedures; prepare in biologic cabinet using gown, gloves, mask; do not allow product to come in contact with skin; use soap and water if contact occurs</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x4434">
									<item>
										<label>•</label>
										<para>EPINEPHrine, antihistamines, corticosteroids for hypersensitivity reaction</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x4442">
								<label>•</label>
								<sec_title>Lyophilized powder</sec_title>
								<para>
									<list id="lidelem4x4442">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Lyophilized powder:</emphasis> reconstitute vial 50 mg/10 ml or 100 mg/20 ml sterile water for inj or D<emphasis style="inf">5</emphasis>W; after reconstitution, sol may be stored for ≤24 hr in refrigerator; after dilution in 250-500 ml D<emphasis style="inf">5</emphasis>W, may store ≤24 hr in refrigerator or 6 hr at room temperature; infuse over 2 hr</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x4456">
								<label>•</label>
								<sec_title>Aqueous solution</sec_title>
								<para>
									<list id="lidelem4x4456">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Aqueous solution:</emphasis> dilute in 250-500 ml of D<emphasis style="inf">5</emphasis>W; after dilution, may store ≤24 hr refrigerator, 6 hr at room temperature, infuse over 2 hr</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, amifostine, amikacin, aminocaproic acid, amiodarone, amphotericin B colloidal, amphotericin B lipid complex, amphotericin B liposome, ampicillin, ampicillin-sulbactam, anidulafungin, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, ceFAZolin, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DACTINomycin, DAPTOmycin, DAUNOrubicin, dexamethasone, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doxacurium, DOXOrubicin, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, foscarnet, fosphenytoin, furosemide, gatifloxacin, gemcitabine, gemtuzumab, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, inamrinone, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, meperidine, meropenem, mesna, metaraminol, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoMYcin, mitoXANtrone, mivacurium, morphine, nafcillin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, PACLitaxel, palonosetron, pancuronium, PEMEtrexed, pentamidine, pentazocine, phenylephrine, piperacillin, polymyxin B, potassium chloride/phosphates, procainamide, prochlorperazine, promethazine, propranolol, quiNIDine, quinupristin-dalfopristin, ranitidine, rocuronium, sodium acetate/phosphates, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, topotecan, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4467">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4470">
					<section type="none" id="sidelem4x4471">
						<sec_title>CNS:</sec_title>
						<para> Peripheral neuropathy, fatigue, headache, dizziness, insomnia</para>
					</section>
					<section type="none" id="sidelem4x4476">
						<sec_title>CV:</sec_title>
						<para> Cardiac abnormalities, <emphasis style="bold">thromboembolism</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4483">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Decreased visual acuity, tinnitus, hearing loss</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4490">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Severe nausea, vomiting, diarrhea, weight loss,</emphasis> stomatitis, anorexia, gastroesophageal reflux, constipation, dyspepsia, mucositis, flatulence</para>
					</section>
					<section type="none" id="sidelem4x4498">
						<sec_title>GU:</sec_title>
						<para> Hematuria, dysuria, creatinine</para>
					</section>
					<section type="none" id="sidelem4x4503">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, pancytopenia, neutropenia, anemia, hemolytic uremic syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4510">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Alopecia,</emphasis> rash, flushing, extravasation, redness, swelling, pain at inj site</para>
					</section>
					<section type="none" id="sidelem4x4518">
						<sec_title>META:</sec_title>
						<para> Hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x4523">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Fibrosis,</emphasis> dyspnea, cough, rhinitis, URI, pharyngitis</para>
					</section>
					<section type="none" id="sidelem4x4531">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4538">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver, excreted in urine; after administration, 15% of platinum in systemic circulation, 85% either in tissues or being eliminated in urine; half-life 390 hr; protein binding &gt;90%</para>
			</section>
			<section type="interactions" id="sidelem4x4543">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, alcohol, anticoagulants, platelet inhibitors, thrombolytics, salicylates</para>
				<para>
					<emphasis alert="lifethreat">Increase: oxaliplatin toxicity—tannins</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—myelosuppressive agents, radiation</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> nephrotoxicity—aminoglycosides, loop diuretics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody response—live virus vaccines</para>
				<section type="none" id="sidelem4x4566">
					<section type="none" id="sidelem4x4567">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST, bilirubin, creatinine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium, neutrophils, WBC, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4578">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4581">
					<section type="none" id="sidelem4x4582">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4588">
								<item>
									<para>
										<emphasis alert="nurse">Bone marrow depression: CBC, differential, platelet count each cycle; withhold product if WBC is &lt;4000 or platelet count is &lt;100,000; notify prescriber of results</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4596">
							<para>
								<list id="lidelem4x4596">
									<item>
										<label>•</label>
										<para>Renal/hepatic studies: BUN, creatinine, serum uric acid, urine CCr before, electrolytes during therapy; dose should not be given if BUN &gt;19 mg/dl; creatinine &lt;1.5 mg/dl; I&amp;O ratio; report fall in urine output of &lt;30 ml/hr; LFTs
<bbw>
												<emphasis alert="lifethreat">Anaphylaxis:</emphasis> wheezing, tachycardia, facial swelling, fainting; discontinue product, report to prescriber; resuscitation equipment should be nearby</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4610">
								<item>
									<para>
										<emphasis alert="nurse">Pulmonary fibrosis: cough, crackles, dyspnea, pulmonary infiltrate; discontinue immediately, death may occur</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4615">
								<item>
									<label>•</label>
									<para>Monitor temperature; may indicate beginning infection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4620">
								<item>
									<label>•</label>
									<para>Hepatic studies before each cycle (bilirubin, AST, ALT, LDH) as needed or monthly</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4628">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x4628">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> hematuria, guaiac, bruising or petechiae, mucosa or orifices; obtain prescription for viscous lidocaine (Xylocaine)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4632">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4637">
								<item>
									<label>•</label>
									<para>Edema in feet, joint pain, stomach pain, shaking</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4642">
								<item>
									<label>•</label>
									<para>Comprehensive oral hygiene</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4647">
								<item>
									<label>•</label>
									<para>All medications PO if possible; avoid IM inj when platelets &lt;100,000/mm<emphasis style="sup">3</emphasis></para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4654">
								<item>
									<label>•</label>
									<para>Increase fluid intake to 2-3 L/day to prevent urate deposits, calculi formation; elimination of product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4659">
								<item>
									<label>•</label>
									<para>Blankets, hat, gloves for cold prevention</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4664">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4668">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4674">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4680">
								<item>
									<para>
										<emphasis alert="nurse">To report signs of infection: increased temperature, sore throat, flulike symptoms</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4688">
							<label>•</label>
							<sec_title>anemia</sec_title>
							<para>
								<list id="lidelem4x4688">
									<item>
										<label>•</label>
										<para>To report signs of <emphasis style="bold">anemia:</emphasis> fatigue, headache, faintness, SOB, irritability</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4696">
							<label>•</label>
							<sec_title>
								<route>bleeding;</route>
							</sec_title>
							<para>
								<list id="lidelem4x4696">
									<item>
										<label>•</label>
										<para>To report  to avoid use of razors, commercial mouthwash</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4701">
								<item>
									<label>•</label>
									<para>To avoid aspirin, ibuprofen, NSAIDs, alcohol; may cause GI bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4707">
								<item>
									<para>
										<emphasis alert="nurse">To report any changes in breathing, coughing</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4712">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that a wig or hairpiece may make patient feel better; that new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4717">
								<item>
									<label>•</label>
									<para>To report numbness, tingling in face or extremities, poor hearing, or joint pain or swelling</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4722">
								<item>
									<label>•</label>
									<para>Not to receive vaccines during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4728">
								<item>
									<para>
										<emphasis alert="nurse">To use contraception during treatment and for 4 mo after; that product may cause infertility, pregnancy (D)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4736">
							<label>•</label>
							<sec_title>Dysesthesias</sec_title>
							<para>
								<list id="lidelem4x4736">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Dysesthesias:</emphasis> to avoid contact with cold (air, ice, liquid)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="19" status="active" ha="yes">
			<mono_name> oxazepam (Rx)</mono_name>
			<info>
				<pronunciation>(ox-ay′ze-pam)</pronunciation>
				<class type="func"> Sedative/hypnotic; antianxiety</class>
				<class type="chem"> Benzodiazepine, short acting</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule></class>
			</info>
			<section type="actions" id="sidelem4x4757">
				<sec_title>Action:</sec_title>
				<para>Potentiates the actions of GABA, especially in the limbic system and the reticular formation</para>
			</section>
			<section type="uses" id="sidelem4x4763">
				<sec_title>Uses:</sec_title>
				<para>Anxiety, alcohol withdrawal</para>
				<section type="none" id="sidelem4x4768">
					<section type="none" id="sidelem4x4769">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Insomnia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4774">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, children &lt;6 yr, hypersensitivity to benzodiazepines, closed-angle glaucoma, psychosis</para>
				<section type="none" id="sidelem4x4779">
					<section type="none" id="sidelem4x4780">
						<sec_title>Precautions:</sec_title>
						<para> Geriatric patients, debilitated, renal/hepatic disease, depression, suicidal ideation, dementia, sleep apnea, seizure disorder, respiratory depression</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4785">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4788">
					<section type="none" id="sidelem4x4789">
						<sec_title>Anxiety</sec_title>
						<section type="none" id="sidelem4x4797">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4797">
									<item>
										<label>•</label>
										<para> 10-15 mg tid-qid, max 120 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4804">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4804">
									<item>
										<label>•</label>
										<para> 10 mg daily-bid, max 60 mg/day tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4808">
						<sec_title>Alcohol withdrawal</sec_title>
						<section type="none" id="sidelem4x4816">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4816">
									<item>
										<label>•</label>
										<para> 15-30 mg tid-qid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4820">
						<sec_title>Available forms:</sec_title>
						<para> Caps 10, 15, 30 mg</para>
					</section>
					<section type="none" id="sidelem4x4825">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4829">
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4835">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4838">
					<section type="none" id="sidelem4x4839">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> confusion, headache, anxiety, tremors, fatigue, depression, insomnia, hallucinations, paradoxical excitement, transient amnesia</para>
					</section>
					<section type="none" id="sidelem4x4847">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis><emphasis style="bold">ECG changes, tachycardia,</emphasis> hypotension</para>
					</section>
					<section type="none" id="sidelem4x4857">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision,</emphasis> tinnitus, mydriasis</para>
					</section>
					<section type="none" id="sidelem4x4865">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia</para>
					</section>
					<section type="none" id="sidelem4x4870">
						<sec_title>HEMA:</sec_title>
						<para> Leukopenia</para>
					</section>
					<section type="none" id="sidelem4x4875">
						<sec_title>INTEG:</sec_title>
						<para> Rash, dermatitis, itching</para>
					</section>
					<section type="none" id="sidelem4x4880">
						<sec_title>SYST:</sec_title>
						<para> Dependence</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4885">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 2-4 hr; metabolized by liver; excreted by kidneys; half-life 5-15 hr; crosses placenta, breast milk; protein binding 97%</para>
			</section>
			<section type="interactions" id="sidelem4x4890">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> oxazepam effects—CNS depressants, alcohol, disulfiram, oral contraceptives</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> oxazepam effects—oral contraceptives, phenytoin, theophylline, valproic acid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of levodopa</para>
				<section type="none" id="sidelem4x4905">
					<section type="none" id="sidelem4x4906">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava, melatonin, valerian</para>
					</section>
					<section type="none" id="sidelem4x4913">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, serum bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4924">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4927">
					<section type="none" id="sidelem4x4928">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4933">
								<item>
									<label>•</label>
									<para>B/P (lying, standing), pulse; if systolic B/P drops 20 mm Hg, hold product, notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4939">
								<item>
									<para>
										<emphasis alert="nurse">Mental status: mood, sensorium, affect, sleeping pattern, drowsiness, dizziness, suicidal thoughts/behaviors</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4945">
								<item>
									<para>
										<emphasis alert="nurse">Physical dependency, withdrawal symptoms: headache, nausea, vomiting, muscle pain, weakness, tremors, seizures (long-term use)</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4950">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4954">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anxiety, restlessness, insomnia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4960">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4965">
								<item>
									<label>•</label>
									<para>That product may be taken without regard to food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4970">
								<item>
									<label>•</label>
									<para>That medication not to be used for everyday stress or used &gt;4 mo unless directed by prescriber; not to take more than prescribed dose because product may be habit forming</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4975">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations (cough, cold, hay fever) unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4980">
								<item>
									<label>•</label>
									<para>To avoid driving, activities that require alertness because drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4985">
								<item>
									<label>•</label>
									<para>To avoid alcohol, other psychotropic products unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4990">
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly after long-term use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4995">
								<item>
									<label>•</label>
									<para>To rise slowly because fainting may occur, especially among geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5000">
								<item>
									<label>•</label>
									<para>That drowsiness may worsen at beginning of treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5009">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected pregnancy (D)</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>OXcarbazepine (Rx)</mono_name>
			<info>
				<pronunciation>(ox′kar-baz′uh-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x50171">Trileptal</tradename>
					<tradename id="tnidelem4x50170">Oxtellar XR</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant</class>
				<class type="chem"> CarBAMazepine analog</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x5027">
				<sec_title>Action:</sec_title>
				<para>May inhibit nerve impulses by limiting influx of sodium ions across cell membrane in motor cortex</para>
			</section>
			<section type="uses" id="sidelem4x5032">
				<sec_title>Uses:</sec_title>
				<para>Partial seizures</para>
				<section type="none" id="sidelem4x5037">
					<section type="none" id="sidelem4x5038">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Trigeminal neuralgia, atypical panic disorder, bipolar disorder</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5043">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x5048">
					<section type="none" id="sidelem4x5049">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;4 yr, hypersensitivity to carBAMazepine, renal disease, fluid restriction, hyponatremia, abrupt discontinuation, suicidal ideation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5054">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5057">
					<section type="none" id="sidelem4x5058">
						<sec_title>Seizures, adjunctive therapy</sec_title>
						<section type="none" id="sidelem4x5066">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5066">
									<item>
										<label>•</label>
										<para> 300 mg bid, may be increased by 600 mg/day in divided doses bid at weekly intervals; maintenance 1200 mg/day; ext rel; 600 mg daily × 1 wk, increase weekly in 600 mg/day increments to 1200-2400 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5073">
							<label>•</label>
							<sec_title>Child 4-16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5073">
									<item>
										<label>•</label>
										<para> 8-10 mg/kg/day divided bid; dose determined by weight, increase by 5 mg/kg/day q3days, max doses weight dependent</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5077">
						<sec_title>Conversion to monotherapy for partial seizures</sec_title>
						<section type="none" id="sidelem4x5085">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5085">
									<item>
										<label>•</label>
										<para> 300 mg bid with reduction in other anticonvulsants; increase OXcarbazepine by 600 mg/day each week over 2-4 wk; withdraw other anticonvulsants over 3-6 wk; max 2400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5089">
						<sec_title>Initiation of monotherapy for partial seizures</sec_title>
						<section type="none" id="sidelem4x5097">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5097">
									<item>
										<label>•</label>
										<para> 300 mg bid, increase by 300 mg/day q3days to 1200 mg in divided doses bid, max 2400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5101">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x5109">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min, 150 mg bid, increase slowly</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5112">
						<sec_title>Bipolar disorder/trigeminal neuralgia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5120">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5120">
									<item>
										<label>•</label>
										<para> 300 mg bid, may increase by ≤600 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5124">
						<sec_title>Available forms:</sec_title>
						<para> Film-coated tabs 150, 300, 600 mg; oral susp 300 mg/5 ml; ext rel tab 150, 300, 600 mg</para>
					</section>
					<section type="none" id="sidelem4x5129">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5132">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x5137">
									<item>
										<label>•</label>
										<para>Without regard to meals</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5145">
								<label>•</label>
								<sec_title>Oral susp</sec_title>
								<para>
									<list id="lidelem4x5145">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral susp:</emphasis> shake well, use calibrated oral syringe provided, use or discard within 7 days of opening</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x5152">
								<label>•</label>
								<sec_title>Ext rel</sec_title>
								<para>
									<list id="lidelem4x5152">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Ext rel:</emphasis> do not crush, break, or chew</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x5156">
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5161">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5164">
					<section type="none" id="sidelem4x5165">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness, confusion, fatigue,</emphasis> feeling abnormal, ataxia, abnormal gait, tremors, anxiety, agitation, <emphasis style="bold">worsening of seizures, suicidal thoughts/behaviors</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5175">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension,</emphasis> chest pain, edema, bradycardia, syncope</para>
					</section>
					<section type="none" id="sidelem4x5183">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision, diplopia, nystagmus,</emphasis> rhinitis, sinusitis</para>
					</section>
					<section type="none" id="sidelem4x5191">
						<sec_title>ENDO:</sec_title>
						<para> Hypothyroidism, hot flashes</para>
					</section>
					<section type="none" id="sidelem4x5196">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, constipation, diarrhea,</emphasis> anorexia, vomiting, abdominal pain, gastritis</para>
					</section>
					<section type="none" id="sidelem4x5204">
						<sec_title>GU:</sec_title>
						<para> Urinary frequency, hematuria, menses change</para>
					</section>
					<section type="none" id="sidelem4x5209">
						<sec_title>INTEG:</sec_title>
						<para> Purpura, rash, acne</para>
					</section>
					<section type="none" id="sidelem4x5214">
						<sec_title>META:</sec_title>
						<para> Hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x5219">
						<sec_title>RESP:</sec_title>
						<para> Flulike symptoms</para>
					</section>
					<section type="none" id="sidelem4x5224">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema, anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5231">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x5234">
					<section type="none" id="sidelem4x5235">
						<sec_title>PO:</sec_title>
						<para> Onset unknown; peak 4-6 hr; metabolized by liver to active metabolite; terminal half-life 7-9 hr metabolite; inhibits P450 CYP2C19, induces CYP3A4/5, 95% renal extraction</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5241">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Contraindicated: MAOIs, ranolazine, nisoldipine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects—felodipine, oral contraceptive, carBAMazepine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> OXcarbazepine levels—carBAMazepine, PHENobarbital, phenytoin, valproic acid, verapamil</para>
				<section type="none" id="sidelem4x5261">
					<section type="none" id="sidelem4x5262">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> anticonvulsant effect—ginkgo</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> anticonvulsant effect—ginseng, santonica</para>
					</section>
					<section type="none" id="sidelem4x5273">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> sodium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5280">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5283">
					<section type="none" id="sidelem4x5284">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5289">
								<item>
									<label>•</label>
									<para>Description of seizures: frequency, duration, aura</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5294">
								<item>
									<label>•</label>
									<para>Hyponatremia: headache, nausea, confusion, usually within the first 3 mo of treatment, but may occur ≤1 yr, if this product is being used with other products that decrease sodium, monitor sodium levels</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5299">
								<item>
									<label>•</label>
									<para>Electrolyte: sodium; T<emphasis style="inf">4</emphasis>; phenytoin (when given together)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5308">
								<item>
									<para>
										<emphasis alert="nurse">Serious reactions: angioedema, anaphylaxis, Stevens-Johnson syndrome</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5316">
							<label>•</label>
							<sec_title>
								<route>suicidal thoughts/behaviors;</route>
							</sec_title>
							<para>
								<list id="lidelem4x5316">
									<item>
										<label>•</label>
										<para>CNS/mental status: mood, sensorium, affect, behavioral changes, confusion,  if mental status changes, notify prescriber</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5321">
								<item>
									<label>•</label>
									<para>Eye problems: need for ophthalmic exams before, during, after treatment (slit lamp, funduscopy, tonometry)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5329">
							<label>•</label>
							<sec_title>Pregnancy<route> lack of seizure control due to MHD, a metabolite of OXcarbazepine, monitor seizure control</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5332">
								<item>
									<label>•</label>
									<para>May monitor target serum level 12-30 mcg/ml to identify compliance/toxicity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5337">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5341">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased seizure activity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5347">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5352">
								<item>
									<label>•</label>
									<para>To avoid driving, other activities that require alertness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5357">
								<item>
									<label>•</label>
									<para>To take twice a day at same intervals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5362">
								<item>
									<label>•</label>
									<para>Not to discontinue medication quickly after long-term use, seizures may increase</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5367">
								<item>
									<label>•</label>
									<para>To inform prescriber if hypersensitive to carBAMazepine; multisystem hypersensitivity may occur; to report fever, other allergic symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5372">
								<item>
									<label>•</label>
									<para>To avoid use of alcohol while taking product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5377">
								<item>
									<label>•</label>
									<para>To use alternative contraception if using hormonal method; to report if pregnancy is planned or suspected (C)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5385">
							<label>•</label>
							<sec_title>
								<route>To report skin rashes immediately, serious skin reactions can occur</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x5391">
							<label>•</label>
							<sec_title>
								<route>To report suicidal thoughts/behavior immediately</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x5394">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Activated charcoal; give 0.9% NaCl (hypotensive state), atropine (bradycardia); use benzodiazepines, barbiturates for seizures</para>
			</section>
		</monograph>
<monograph id="21" status="active">
			<mono_name>oxybutynin (Rx, <emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(ox-i-byoo′ti-nin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x54075">
						<country code="CAN">Ditropan </country>
					</tradename>
					<tradename id="tnidelem4x54074">Ditropan XL</tradename>
					<tradename id="tnidelem4x54073">Gelnique</tradename>
					<tradename id="tnidelem4x54072">
						<country code="CAN">Oxytrol </country>
					</tradename>
					<tradename id="tnidelem4x54071">Oxytrol Transdermal</tradename>
					<tradename id="tnidelem4x54070">
						<country code="CAN">Uromax </country>
					</tradename>
				</tradenames>
				<class type="func"> Anticholinergic</class>
				<class type="chem"> Synthetic tertiary amine</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x5425">
				<para>
					<confusion>
						<tradename id="tnidelem4x54250">Ditropan</tradename>
						<drug type="generic" refid="idelem4x54250">diazepam</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5429">
				<sec_title>Action:</sec_title>
				<para>Relaxes smooth muscles in urinary tract by inhibiting acetylcholine at postganglionic sites</para>
			</section>
			<section type="uses" id="sidelem4x5434">
				<sec_title>Uses:</sec_title>
				<para>Antispasmodic for neurogenic bladder, overactive bladder in females (OTC)</para>
			</section>
			<section type="contra" id="sidelem4x5439">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, GI obstruction, urinary retention, glaucoma, severe colitis, myasthenia gravis, unstable CV disease</para>
				<section type="none" id="sidelem4x5444">
					<section type="none" id="sidelem4x5445">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children &lt;12 yr, geriatric patients, suspected glaucoma, cardiac disease, dementia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5451">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5459">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5459">
							<item>
								<label>•</label>
								<para> 5 mg bid-tid, max 5 mg qid;  5-10 mg/day, may increase by 5 mg, max 30 mg/day;  apply 1 patch to abdomen, hip, buttock 2×/wk (q3-4 days);  apply contents of 1 packet to abdomen, upper arms, shoulders, thighs daily</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5475">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5475">
							<item>
								<label>•</label>
								<para> 2.5-5 mg bid-tid, increase by 2.5 mg q several days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5482">
					<label>•</label>
					<sec_title>Child &gt;6 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5482">
							<item>
								<label>•</label>
								<para> 5 mg bid, max 5 mg tid;  5 mg/day, max 20 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5492">
					<label>•</label>
					<sec_title>Child 1-5 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5492">
							<item>
								<label>•</label>
								<para> 0.2 mg/kg/dose bid-tid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5496">
					<section type="none" id="sidelem4x5497">
						<sec_title>Available forms:</sec_title>
						<para> Syr 5 mg/5 ml; tabs 5 mg; ext rel tabs 5, 10, 15 mg; TD 3.9 mg/day; top gel 10% (Gelnique)</para>
					</section>
					<section type="none" id="sidelem4x5502">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5505">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x5509">
									<item>
										<label>•</label>
										<para>Do not crush, break, or chew ext rel tabs</para>
									</item>
									<item>
										<label>•</label>
										<para>Without regard to meals</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5520">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x5524">
									<item>
										<label>•</label>
										<para>Wash hands; apply to clean, dry, intact skin on abdomen, upper arms/shoulders, thighs; avoid navel, rotate sites</para>
									</item>
									<item>
										<label>•</label>
										<para>Squeeze contents into palm of hand or directly on site, rub gently</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not bathe, exercise, swim for 1 hr after application</para>
									</item>
									<item>
										<label>•</label>
										<para>Allow to dry before putting on clothing</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not be near flame, fire, or smoke until gel has dried</para>
									</item>
									<item>
										<label>•</label>
										<para>Delivers 100 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5555">
							<sec_title>Transdermal route</sec_title>
							<para>
								<list id="lidelem4x5559">
									<item>
										<label>•</label>
										<para>Apply to clean, dry, intact skin on abdomen, hip, buttock; use firm pressure; not affected by showering/bathing; rotate sites</para>
									</item>
									<item>
										<label>•</label>
										<para>Delivers 3.9 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5570">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5573">
					<section type="none" id="sidelem4x5574">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Anxiety, restlessness, dizziness, somnolence, insomnia, nervousness,</emphasis><emphasis style="bold">seizures,</emphasis> headache, <emphasis style="italic">drowsiness,</emphasis> confusion</para>
					</section>
					<section type="none" id="sidelem4x5587">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Palpitations, sinus tachycardia,</emphasis> hypertension, peripheral edema, <emphasis style="bold">QT prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5597">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision, dry eyes,</emphasis> increased intraocular tension, <emphasis style="italic">dry mouth,</emphasis> throat</para>
					</section>
					<section type="none" id="sidelem4x5608">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia,</emphasis> abdominal pain, <emphasis style="italic">constipation, dyspepsia,</emphasis> diarrhea, taste perversion, GERD</para>
					</section>
					<section type="none" id="sidelem4x5619">
						<sec_title>GU:</sec_title>
						<para> Dysuria, impotence, <emphasis style="italic">urinary retention, hesitancy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5626">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Hyperthermia, anaphylaxis, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5633">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr, peak 3-6 hr, duration 6-10 hr; metabolized by liver, excreted in urine; terminal half-life 2-3 hr</para>
			</section>
			<section type="interactions" id="sidelem4x5644">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x5648">
						<item>
							<label>•</label>
							<para>Altered pharmacokinetic parameters: CYP3A4 inhibitors</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—benzodiazepines, sedatives, hypnotics, opioids</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of atenolol, digoxin, nitrofurantoin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic effects—antihistamines, amantidine, other anticholinergics</para>
				<para>
					<emphasis style="bold">Increase or decrease:</emphasis> levels of phenothiazines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of acetaminophen, haloperidol, levodopa</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of oxybutynin—CYP3A4 inducers</para>
			</section>
			<section type="considerations" id="sidelem4x5678">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5681">
					<section type="none" id="sidelem4x5682">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5690">
							<label>•</label>
							<sec_title>Urinary patterns</sec_title>
							<para>
								<list id="lidelem4x5690">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Urinary patterns:</emphasis> distention, nocturia, frequency, urgency, incontinence, I&amp;O ratios; cystometry to diagnose dysfunction, urinary tract infections should be treated</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5695">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions: rash, urticaria; if these occur, product should be discontinued; angioedema</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5701">
								<item>
									<para>
										<emphasis alert="nurse">QT prolongation: ECG for QT prolongation, ejection fraction; assess for chest pain, palpitations, dyspnea</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5706">
								<item>
									<label>•</label>
									<para>CNS effects: confusion, anxiety; anticholinergic effects in geriatric patients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5711">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5715">
								<item>
									<label>•</label>
									<para>Urinary status: dysuria, frequency, nocturia, incontinence</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5721">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5726">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities because dizziness, blurred vision may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5732">
								<item>
									<label>•</label>
									<para>To avoid OTC medications with alcohol, other CNS depressants</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5737">
								<item>
									<label>•</label>
									<para>To avoid hot weather, strenuous activity because product decreases perspiration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5742">
								<item>
									<label>•</label>
									<para>About the correct application of each product form</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5750">
							<label>•</label>
							<sec_title>Transdermal</sec_title>
							<para>
								<list id="lidelem4x5750">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Transdermal:</emphasis> change patch 2×/wk; do not use same site within 7 days; dispose of and use container not accessible to pets/children</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5754">
								<item>
									<label>•</label>
									<para>To open patch immediately before using</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5759">
								<item>
									<label>•</label>
									<para>Do not use during MRI, remove</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5767">
							<label>•</label>
							<sec_title>Topical gel</sec_title>
							<para>
								<list id="lidelem4x5767">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Topical gel:</emphasis> rotate sites</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5771">
								<item>
									<label>•</label>
									<para>Apply to clean, dry skin on abdomen, upper arm/shoulders/thighs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5776">
								<item>
									<label>•</label>
									<para>Gel is flammable</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="22" status="active" ha="yes">
			<mono_name> oxyCODONE (Rx)</mono_name>
			<info>
				<pronunciation>(ox-i-koe′done)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x57884">Oxecta</tradename>
					<tradename id="tnidelem4x57883">Oxy-CONTIN</tradename>
					<tradename id="tnidelem4x57882">
						<country code="CAN">Oxy IR</country>
					</tradename>
					<tradename id="tnidelem4x57881">Roxicodone</tradename>
					<tradename id="tnidelem4x57880">
						<country code="CAN">Supeudol </country>
					</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="23" status="active">
			<mono_name>oxyCODONE/aspirin (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x57981">Endodan</tradename>
					<tradename id="tnidelem4x57980">Percodan</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="24" status="active">
			<mono_name>oxyCODONE/acetaminophen (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x58037">Endocet</tradename>
					<tradename id="tnidelem4x58036">Oxycet</tradename>
					<tradename id="tnidelem4x58035">Percocet</tradename>
					<tradename id="tnidelem4x58034">Primalev</tradename>
					<tradename id="tnidelem4x58033">Roxicet</tradename>
					<tradename id="tnidelem4x58032">Roxilox</tradename>
					<tradename id="tnidelem4x58031">Tylox</tradename>
					<tradename id="tnidelem4x58030">Xartemis</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="25" status="active">
			<mono_name>oxyCODONE/ibuprofen (Rx)</mono_name>
			<info>
				<class type="func"> Opiate analgesic</class>
				<class type="chem"> Semisynthetic derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="2">II</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x5818">
				<para>
					<confusion>
						<tradename id="tnidelem4x58180">Percodan</tradename>
						<drug type="generic" refid="idelem4x58180">Decadron</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5837">
				<sec_title>Action:</sec_title>
				<para>Inhibits ascending pain pathways in CNS, increases pain threshold, alters pain perception</para>
			</section>
			<section type="uses" id="sidelem4x5842">
				<sec_title>Uses:</sec_title>
				<para>Moderate to severe pain</para>
				<section type="none" id="sidelem4x5847">
					<section type="none" id="sidelem4x5848">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Postherpetic neuralgic (cont rel)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5853">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, addiction (opiate), asthma, ileus</para>
				<para>
					<bbw>Respiratory depression</bbw>
				</para>
				<section type="none" id="sidelem4x5868">
					<section type="none" id="sidelem4x5869">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, child &lt;18 yr, addictive personality, increased intracranial pressure, MI (acute), severe heart disease, renal/hepatic disease, bowel impaction</para>
						<para>
							<bbw>Opioid-naive patients, substance abuse, accidental exposure, potential for overdose/poisoning, status asthmaticus</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5884">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5892">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5892">
							<item>
								<label>•</label>
								<para> 10-30 mg q4hr (5-15 mg q4-6hr for opiate-naive patients)  10 mg q12hr for opiate-naive patients</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5899">
					<section type="none" id="sidelem4x5900">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">OxyCODONE:</emphasis> cont rel tabs (OxyCONTIN) 10, 15, 20, 30, 40, 80, 160 mg; immediate rel tabs 5, 7.5, 10, 15, 20, 30 mg; immediate rel caps 5 mg; oral sol 5 mg/5 ml, 20 mg/ml; <emphasis style="bold">oxyCODONE with acetaminophen:</emphasis> 2.5 mg/325 mg, 5 mg/325 mg, 7.5 mg/325 mg, 7.5 mg/300 mg, 10 mg/325 mg, oral sol 5 mg/325 mg/5 ml; <emphasis style="bold">oxyCODONE with aspirin:</emphasis> 4.88/325 mg; <emphasis style="bold">oxyCODONE with ibuprofen:</emphasis> 5 mg/400 mg</para>
					</section>
					<section type="none" id="sidelem4x5917">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5921">
								<item>
									<label>•</label>
									<para>Store in light-resistant area at room temperature</para>
								</item>
								<item>
									<label>•</label>
									<para>OxyCODONE should be titrated from the initial recommended dosage to the dosage required to relieve pain</para>
								</item>
								<item>
									<label>•</label>
									<para>There is no maximum dosage of oxyCODONE; however, careful titration is required until tolerance develops to some of the side effects (drowsiness, respiratory depression)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5938">
						<sec_title>Oral solid formulations</sec_title>
						<section type="none" id="sidelem4x5941">
							<sec_title>Immediate-release tablets route</sec_title>
							<para>
								<list id="lidelem4x5946">
									<item>
										<label>•</label>
										<para>May be administered with food or milk to minimize GI irritation</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5954">
								<label>•</label>
								<sec_title>Oxecta brand tablets</sec_title>
								<para>
									<list id="lidelem4x5954">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oxecta brand tablets:</emphasis> swallow whole; do not crush or dissolve; owing to nature of this formulation, do not presoak, lick, or otherwise wet tablet before administering dose; administer 1 tablet at a time; allow patient to swallow each tablet separately with sufficient liquid to ensure prompt and complete transit through the esophagus; do not use this brand for administration via nasogastric, gastric, or other feeding tubes because it can obstruct feeding tubes</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
					<section type="none" id="sidelem4x5958">
						<sec_title>Oral solid formulations</sec_title>
						<section type="none" id="sidelem4x5961">
							<sec_title>Controlled-release tablets route (OxyCONTIN):</sec_title>
							<para>
								<list id="lidelem4x5966">
									<item>
										<label>•</label>
										<para>Administer whole; do not crush, chew, or break in half; taking chewed, broken, or crushed controlled-release tablets could lead to the rapid release and absorption of a potentially toxic dose of oxyCODONE</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5974">
								<label>•</label>
								<sec_title>OxyCONTIN brand tablets</sec_title>
								<para>
									<list id="lidelem4x5974">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">OxyCONTIN brand tablets:</emphasis> owing to hydro-gelling nature of the 2010 reformulation, do not presoak, lick, or otherwise wet tablet before administering dose; administer 1 tablet at a time; allow patient to swallow each tablet separately with sufficient liquid to ensure prompt and complete transit through the esophagus</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x5981">
								<label>•</label>
								<sec_title>
									<route>OxyCODONE controlled-release (OxyCONTIN)</route>
								</sec_title>
								<para>
									<list id="lidelem4x5981">
										<item>
											<label>•</label>
											<para> 60-mg and 80-mg tablets are for use only in opioid-tolerant patients</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x5985">
									<item>
										<label>•</label>
										<para>May be administered without food</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5990">
						<sec_title>Oral liquid formulations</sec_title>
						<section type="none" id="sidelem4x5993">
							<sec_title>Oral concentrate solution route</sec_title>
							<section type="none" id="sidelem4x6001">
								<label>•</label>
								<sec_title>
									<route>OxyFAST</route>
								</sec_title>
								<para>
									<list id="lidelem4x6001">
										<item>
											<label>•</label>
											<para> is a highly concentrated sol (20 mg oxyCODONE/ml), and care should be taken in dispensing and administering this medication; for ease of administration, the sol may be added to 30 ml of a liquid or semisolid food; if the medication is placed in liquid or food, the patient needs to consume it immediately; do not store diluted oxyCODONE for future use</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6005">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6008">
					<section type="none" id="sidelem4x6009">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, dizziness, confusion, headache, sedation, euphoria,</emphasis> fatigue, abnormal dreams/thoughts, hallucinations</para>
					</section>
					<section type="none" id="sidelem4x6017">
						<sec_title>CV:</sec_title>
						<para> Palpitations, <emphasis style="bold">bradycardia,</emphasis> change in B/P</para>
					</section>
					<section type="none" id="sidelem4x6025">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, blurred vision, miosis, diplopia</para>
					</section>
					<section type="none" id="sidelem4x6030">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, constipation, cramps,</emphasis> gastritis, dyspepsia, biliary spasms</para>
					</section>
					<section type="none" id="sidelem4x6038">
						<sec_title>GU:</sec_title>
						<para> Increased urinary output, dysuria, urinary retention</para>
					</section>
					<section type="none" id="sidelem4x6043">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, bruising, flushing, diaphoresis, pruritus</para>
					</section>
					<section type="none" id="sidelem4x6051">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6058">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x6061">
					<section type="none" id="sidelem4x6062">
						<sec_title>PO:</sec_title>
						<para> Onset 15-30 min, peak 1 hr, duration reg rel 2-6 hr, cont rel 12 hr, metabolized by liver, excreted in urine, crosses placenta, excreted in breast milk, half-life 3-5 hr, protein binding 45%</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6067">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects with other CNS depressants—alcohol, opioids, sedative/hypnotics, antipsychotics, skeletal muscle relaxants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> oxyCODONE level: CYP3A4 inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—cimetidine, MAOIs</para>
				<section type="none" id="sidelem4x6082">
					<section type="none" id="sidelem4x6083">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> sedative effect—kava, St. John’s wort, valerian</para>
					</section>
					<section type="none" id="sidelem4x6090">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> amylase, lipase</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6097">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6100">
					<section type="none" id="sidelem4x6101">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6109">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x6109">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> intensity, location, type, characteristics; need for pain medication by pain/sedation scoring; physical dependence</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6113">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for decreasing output; may indicate urinary retention</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6121">
							<label>•</label>
							<sec_title>CNS changes</sec_title>
							<para>
								<list id="lidelem4x6121">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CNS changes:</emphasis> dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6128">
							<label>•</label>
							<sec_title>Allergic reactions</sec_title>
							<para>
								<list id="lidelem4x6128">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reactions:</emphasis> rash, urticaria
<bbw>
												<emphasis alert="lifethreat">Respiratory dysfunction:</emphasis> respiratory depression, character, rate, rhythm; notify prescriber if respirations are &lt;10/min; B/P, pulse</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6147">
							<label>•</label>
							<sec_title>Bowel status</sec_title>
							<para>
								<list id="lidelem4x6147">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bowel status:</emphasis> constipation; stimulant laxative may be needed with fluids, fiber
<bbw>
												<emphasis alert="lifethreat">Substance abuse:</emphasis> assess for substance abuse in patient/family/friends before prescribing: monitor for abuse</bbw>

<bbw>
												<emphasis alert="lifethreat">Accidental exposure:</emphasis> dispose of properly away from pets, children</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6173">
								<item>
									<label>•</label>
									<para>Assistance with ambulation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6178">
								<item>
									<label>•</label>
									<para>Safety measures: night-light, call bell within easy reach</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6183">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6187">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in pain without dependence</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6193">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6197">
								<item>
									<label>•</label>
									<para>To report any symptoms of CNS changes, allergic reactions</para>
								</item>
								<item>
									<label>•</label>
									<para>That physical dependency may result from extended use</para>
								</item>
								<item>
									<label>•</label>
									<para>That withdrawal symptoms may occur after long-term use: nausea, vomiting, cramps, fever, faintness, anorexia</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid CNS depressants, alcohol</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid driving, operating machinery if drowsiness occurs</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x6223">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Naloxone (Narcan) 0.2-0.8 mg IV, O<emphasis style="inf">2</emphasis>, IV fluids, vasopressors, caution with patients physically dependent on opioids</para>
			</section>
		</monograph>
<monograph id="26" status="active">
			<mono_name>oxymetazoline nasal agent</mono_name>
			<section type="none" id="sidelem4x6234">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="27" status="active">
			<mono_name>oxymetazoline ophthalmic</mono_name>
			<section type="none" id="sidelem4x6241">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="28" status="active" ha="yes">
			<mono_name> oxymorphone (Rx)</mono_name>
			<info>
				<pronunciation>(ox-i-mor′fone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x62521">Opana</tradename>
					<tradename id="tnidelem4x62520">Opana ER</tradename>
				</tradenames>
				<class type="func"> Opiate analgesic</class>
				<class type="chem"> Semisynthetic phenanthrene derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="2">II</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x6264">
				<para>
					<confusion>
						<tradename id="tnidelem4x62640">oxymorphones</tradename>
						<drug type="generic" refid="idelem4x62640">oxyCODONE</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6268">
				<sec_title>Action:</sec_title>
				<para>Inhibits ascending pain pathways in CNS, increases pain threshold, alters pain perception</para>
			</section>
			<section type="uses" id="sidelem4x6273">
				<sec_title>Uses:</sec_title>
				<para>Moderate to severe pain</para>
			</section>
			<section type="contra" id="sidelem4x6278">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, addiction (opiate), asthma, hepatic disease, ileus, intrathecal use, surgery</para>
				<para>
					<bbw>Respiratory depression</bbw>
				</para>
				<section type="none" id="sidelem4x6293">
					<section type="none" id="sidelem4x6294">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>) (short-term), breastfeeding, children &lt;18 yr, addictive personality, increased intracranial pressure, MI (acute), severe heart disease, respiratory depression, renal/hepatic disease, bowel impaction</para>
						<para>
							<bbw>Alcoholism, opioid-naive patients, substance abuse</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6309">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6317">
					<label>•</label>
					<sec_title>Adult<route> IM/SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x6317">
							<item>
								<label>•</label>
								<para> 1 mg q4-6hr prn;  0.5 mg q4-6hr prn; <emphasis style="italic">opiate naive</emphasis> (immediate release only) 5-20 mg q4-6hr prn; <emphasis style="italic">opiate naive</emphasis> 5 mg q12hr in those requiring around-the-clock dosing</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6334">
					<section type="none" id="sidelem4x6335">
						<sec_title>Labor analgesia</sec_title>
						<section type="none" id="sidelem4x6343">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x6343">
									<item>
										<label>•</label>
										<para> 0.5-1 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6347">
						<sec_title>Available forms:</sec_title>
						<para> Inj 1, 1.5 mg/ml; ER tab, crush resistant 5, 7.5, 10, 15, 20, 30, 40 mg; tabs 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x6353">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6357">
								<item>
									<label>•</label>
									<para>1 hr before or 2 hr after food (PO)</para>
								</item>
								<item>
									<label>•</label>
									<para>With antiemetic for nausea, vomiting</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not break, crush, chew ER product</para>
								</item>
								<item>
									<label>•</label>
									<para>When pain is beginning to return; determine interval by response</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in light-resistant area at room temperature</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6383">
						<sec_title>CONTROLLED REL</sec_title>
						<section type="none" id="sidelem4x6391">
							<label>•</label>
							<sec_title>Opiate naive</sec_title>
							<para>
								<list id="lidelem4x6391">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Opiate naive:</emphasis> start with lowest dose, titrate upward 5-10 mg q12hr q3-7days to therapeutic response</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6398">
							<label>•</label>
							<sec_title>
								<route>When converting from immediate rel to ext rel, give 1⁄2 daily dose of ext rel product q12hr</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x6407">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x6411">
									<item>
										<label>•</label>
										<para>Rotate inj sites</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use if respirations are &lt;12/min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6422">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x6426">
									<item>
										<label>•</label>
										<para>Give undiluted over 2-3 min, may be diluted in NS solution</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Glycopyrrolate, hydrOXYzine, ranitidine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6436">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6439">
					<section type="none" id="sidelem4x6440">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, dizziness, confusion, headache,</emphasis> hallucinations, <emphasis style="bold">increased intracranial pressure,</emphasis><emphasis style="italic">sedation,</emphasis><emphasis style="bold">seizures,</emphasis><emphasis style="italic">euphoria (geriatric patients)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6456">
						<sec_title>CV:</sec_title>
						<para> Palpitations, <emphasis style="bold">bradycardia,</emphasis> change in B/P, hypotension</para>
					</section>
					<section type="none" id="sidelem4x6464">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, blurred vision, miosis, diplopia</para>
					</section>
					<section type="none" id="sidelem4x6469">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, constipation, cramps</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6476">
						<sec_title>GU:</sec_title>
						<para> Dysuria, urinary retention</para>
					</section>
					<section type="none" id="sidelem4x6481">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, bruising, flushing, diaphoresis, pruritus</para>
					</section>
					<section type="none" id="sidelem4x6489">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6496">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted in urine, crosses placenta, half life: PO: 7-9 hr, ext rel: 9-11 hr</para>
				<section type="none" id="sidelem4x6501">
					<section type="none" id="sidelem4x6502">
						<sec_title>PO:</sec_title>
						<para> Peak 1 hr (fasting)</para>
					</section>
					<section type="none" id="sidelem4x6507">
						<sec_title>SUBCUT/IM:</sec_title>
						<para> Onset 10-15 min, peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, duration 3-6 hr</para>
					</section>
					<section type="none" id="sidelem4x6518">
						<sec_title>IV:</sec_title>
						<para> Onset 5-10 min, peak 15-30 min, duration 3-6 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6523">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: effects with other CNS depressants—alcohol, opiates, sedative/hypnotics, antipsychotics, skeletal muscle relaxants</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: unpredictable effects/reactions—MAOIs</emphasis>
				</para>
				<section type="none" id="sidelem4x6536">
					<section type="none" id="sidelem4x6537">
						<section type="none" id="sidelem4x6538">
							<sec_title>Drug/Herb</sec_title>
							<para>
								<emphasis style="bold">Increase:</emphasis> sedative effect—kava, St. John’s wort, valerian</para>
						</section>
						<section type="none" id="sidelem4x6545">
							<sec_title>Drug/Lab Test</sec_title>
							<para>
								<emphasis style="bold">Increase:</emphasis> amylase</para>
						</section>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6552">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6555">
					<section type="none" id="sidelem4x6556">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6564">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x6564">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> location, intensity, type, other characteristics before and 1 hr after (IM) IV 30 min; need for pain medication, physical dependence, give 25%-50% until pain reduction of 50% on pain rating scale, repeat dose may be given at time of peak if previous dose does not control pain and respiratory depression has not occurred; give short-acting opioids for breakthrough pain if patient receiving controlled rel product</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6568">
								<item>
									<label>•</label>
									<para>I&amp;O ratio for decreasing output; may indicate urinary retention</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6576">
							<label>•</label>
							<sec_title>Bowel status</sec_title>
							<para>
								<list id="lidelem4x6576">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bowel status:</emphasis> constipation; may need stimulative laxative, increased fluids, fiber</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6583">
							<label>•</label>
							<sec_title>CNS changes</sec_title>
							<para>
								<list id="lidelem4x6583">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CNS changes:</emphasis> dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6590">
							<label>•</label>
							<sec_title>Allergic reactions</sec_title>
							<para>
								<list id="lidelem4x6590">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reactions:</emphasis> rash, urticaria
<bbw>
												<emphasis alert="lifethreat">Respiratory dysfunction:</emphasis> respiratory depression, character, rate, rhythm; notify prescriber if respirations are &lt;10/min</bbw>

<bbw>
												<emphasis alert="lifethreat">Accidental exposure:</emphasis> dispose of properly, away from children/pets</bbw>

<bbw>
												<emphasis alert="lifethreat">Overdose/poisoning:</emphasis> avoid alcohol ingestion, do not crush, chew, snort, or inject tabs, high abuse potential</bbw>

<bbw>
												<emphasis alert="lifethreat">Opioid-naive patients:</emphasis> ext rel tabs are not to be used immediately postop (12-24 hr after surgery) in these patients</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6639">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6643">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6649">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6654">
								<item>
									<label>•</label>
									<para>To report any symptoms of CNS changes, allergic reactions</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6659">
								<item>
									<label>•</label>
									<para>That physical dependency may result from extended use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6664">
								<item>
									<label>•</label>
									<para>That withdrawal symptoms may occur: nausea, vomiting, cramps, fever, faintness, anorexia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6669">
								<item>
									<label>•</label>
									<para>Not to drive or operate machinery if drowsiness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6675">
								<item>
									<para>
										<emphasis alert="nurse">Not to use other CNS depressants, alcohol</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6680">
								<item>
									<label>•</label>
									<para>To make position changes slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x6685">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Naloxone (Narcan) 0.2-0.8 mg IV, (caution with patients physically dependent on opioids) O<emphasis style="inf">2</emphasis>, IV fluids, vasopressors</para>
			</section>
		</monograph>
<monograph id="29" status="active" ha="yes">
			<mono_name> oxytocin (Rx)</mono_name>
			<info>
				<pronunciation>(ox-i-toe′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x67000">Pitocin</tradename>
				</tradenames>
				<class type="func"> Hormone</class>
				<class type="chem"> Oxytocic, uterine-active agent</class>
			</info>
			<section type="actions" id="sidelem4x6710">
				<sec_title>Action:</sec_title>
				<para>Acts directly on myofibrils, thereby producing uterine contraction; stimulates milk ejection by the breast; vasoactive antidiuretic effect</para>
			</section>
			<section type="uses" id="sidelem4x6715">
				<sec_title>Uses:</sec_title>
				<para>Stimulation, induction of labor; missed or incomplete abortion; postpartum bleeding</para>
			</section>
			<section type="contra" id="sidelem4x6720">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, serum toxemia, cephalopelvic disproportion, fetal distress, hypertonic uterus, prolapsed umbilical cord, active genital herpes</para>
				<section type="none" id="sidelem4x6725">
					<section type="none" id="sidelem4x6726">
						<sec_title>Precautions:</sec_title>
						<para> Cervical/uterine surgery, uterine sepsis, primipara &gt;35 yr, 1st/2nd stage of labor</para>
						<para>
							<bbw>Elective induction of labor</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6741">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6744">
					<section type="none" id="sidelem4x6745">
						<sec_title>Postpartum hemorrhage</sec_title>
						<section type="none" id="sidelem4x6753">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6753">
									<item>
										<label>•</label>
										<para> 10-40 units in 1000 ml nonhydrating diluent infused at 20-40 mU/min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6760">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x6760">
									<item>
										<label>•</label>
										<para> 3-10 units after delivery of placenta</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6764">
						<sec_title>Contraction stress test (CST)</sec_title>
						<section type="none" id="sidelem4x6772">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6772">
									<item>
										<label>•</label>
										<para> 0.5 mU/min, increase q20min until 3 contractions within 10 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6776">
						<sec_title>Stimulation of labor</sec_title>
						<section type="none" id="sidelem4x6784">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6784">
									<item>
										<label>•</label>
										<para> 0.5-2 mU/min, increase by 1-2 mU q15-60min until contractions occur, then decrease dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6788">
						<sec_title>Incomplete abortion</sec_title>
						<section type="none" id="sidelem4x6796">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x6796">
									<item>
										<label>•</label>
										<para> 10 units/500 ml D<emphasis style="inf">5</emphasis>W or 0.9% NaCl at 10-20 mU/min, max 30 units/12 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6803">
						<sec_title>Available forms:</sec_title>
						<para> Inj 10 units/ml</para>
					</section>
					<section type="none" id="sidelem4x6808">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6811">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x6815">
									<item>
										<label>•</label>
										<para>Use infusion pump</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6821">
						<sec_title>Labor induction</sec_title>
						<para>
							<list id="lidelem4x6825">
								<item>
									<label>•</label>
									<para>After diluting 10 units/1000 ml of 0.9% NS or D<emphasis style="inf">5</emphasis> NS run at 1-2 mU/min at 15- to 30-min intervals to begin normal labor; dilute 10-40 mU/min; titrate to control postpartum bleeding; dilute 10 units/500 ml sol; run 10 units-20 mU/ml; administer by only 1 route at a time; use infusion pump; rotate infusion to provide mixing; do not shake</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6834">
						<sec_title>Control of postpartum bleeding</sec_title>
						<para>
							<list id="lidelem4x6838">
								<item>
									<label>•</label>
									<para>Dilute 10-40 units/1000 ml of sol; run at 10-20 mU/min; adjust rate as needed</para>
								</item>
								<item>
									<label>•</label>
									<para>With crash cart available on unit (magnesium sulfate at bedside)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6849">
						<sec_title>Incomplete, inevitable, elective abortion</sec_title>
						<para>
							<list id="lidelem4x6853">
								<item>
									<label>•</label>
									<para>Dilute 10 units/500 ml compatible IV sol</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Y-site compatibilities:</emphasis> Heparin, hydrocortisone, insulin (regular), meperidine, morphine, potassium chloride, vit B/C, warfarin</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6865">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6868">
					<section type="none" id="sidelem4x6869">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures, tetanic contractions</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6876">
						<sec_title>CV:</sec_title>
						<para> Hypo/hypertension, dysrhythmias, increased pulse, bradycardia, tachycardia, PVC</para>
					</section>
					<section type="none" id="sidelem4x6881">
						<sec_title>FETUS:</sec_title>
						<para> Dysrhythmias, jaundice, hypoxia, <emphasis style="bold">intracranial hemorrhage</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6888">
						<sec_title>GI:</sec_title>
						<para> Anorexia, nausea, vomiting, constipation</para>
					</section>
					<section type="none" id="sidelem4x6893">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Abruptio placentae, decreased uterine blood flow</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6900">
						<sec_title>HEMA:</sec_title>
						<para> Increased hyperbilirubinemia</para>
					</section>
					<section type="none" id="sidelem4x6905">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x6910">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Asphyxia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6917">
						<sec_title>SYST:</sec_title>
						<para> Water intoxication of mother</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6922">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x6925">
					<section type="none" id="sidelem4x6926">
						<sec_title>IM:</sec_title>
						<para> Onset 3-7 min, duration 1 hr, half-life 12-17 min</para>
					</section>
					<section type="none" id="sidelem4x6931">
						<sec_title>IV:</sec_title>
						<para> Onset 1 min, duration 30 min, half-life 12-17 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6936">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x6940">
						<item>
							<label>•</label>
							<para>Hypertension: vasopressors</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x6946">
					<section type="none" id="sidelem4x6947">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x6951">
								<item>
									<label>•</label>
									<para>Hypertension: ephedra</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6957">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6960">
					<section type="none" id="sidelem4x6961">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6966">
								<item>
									<label>•</label>
									<para>I&amp;O ratio</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6971">
								<item>
									<label>•</label>
									<para>B/P, pulse; watch for changes that may indicate hemorrhage</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6976">
								<item>
									<label>•</label>
									<para>Respiratory rate, rhythm, depth; notify prescriber of abnormalities</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6981">
								<item>
									<label>•</label>
									<para>Length, intensity, duration of contraction; notify prescriber of contractions lasting &gt;1 min or absence of contractions; turn patient on her side; discontinue oxytocin</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6989">
							<label>•</label>
							<sec_title>
								<route>FHTs, fetal distress; watch for acceleration, deceleration; notify prescriber if problems occur; fetal presentation, pelvic dimensions; turn patient on left side if FHT change in rate, give O</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x6996">
								<item>
									<para>
										<emphasis alert="nurse">Water intoxication; confusion, anuria, drowsiness, headache</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7001">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7005">
								<item>
									<label>•</label>
									<para>Therapeutic response: stimulation of labor, control of postpartum bleeding</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7011">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7015">
								<item>
									<label>•</label>
									<para>To report increased blood loss, abdominal cramps, fever, foul-smelling lochia</para>
								</item>
								<item>
									<label>•</label>
									<para>That contractions will be similar to menstrual cramps, gradually increasing in intensity</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>Elective induction of labor: use only for induction when medically necessary</bbw>
						</para>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>